Introduction {#s1}
============

The binding of membrane-bound ligands to their receptors can initiate multiscale spatial reorganization of receptors and their signal transduction machinery. This presumably optimizes receptor signaling and is often driven by remodeling of the cortical cytoskeleton. The formation of an immune synapse between a lymphocyte and an antigen-presenting cell (APC) is an excellent model for studying the dynamic changes in receptor and cytoskeleton organization that occur during cell-cell interactions and how they impact cellular activation ([@bib26]; [@bib41]; [@bib42]; [@bib81]). B lymphocytes play a critical role in health and disease by producing antibodies and cytokines. Although B cells can be activated by the binding of soluble antigens (Ags) to the B cell receptor (BCR), APCs that capture and concentrate Ags are potent activators of B cells ([@bib7]).

The immune synapse is a transient and highly dynamic structure that is characterized by a rapidly evolving reorganization of plasma membrane components and signaling proteins. When B cells encounter Ag on the surface of an APC, BCRs undergo rapid actin-dependent spatial reorganization that amplifies BCR signaling ([@bib41]) and reduces the amount of Ag required for B cell activation ([@bib6]; [@bib23]; [@bib93]). Initial BCR signaling induces localized actin severing and transiently uncouples the cortical cytoskeleton from the plasma membrane ([@bib29]; [@bib39]; [@bib87]). These changes allow for increased mobility of BCRs within the plasma membrane and enable the formation of BCR microclusters that are initially distributed throughout the B cell-APC contact site ([@bib6]; [@bib23]). Because BCR signaling output depends on BCR-BCR interactions, microcluster formation amplifies BCR signaling. BCR clustering leads to phosphorylation of the CD79a/b (Ig-$\alpha$/$\beta$) signaling subunit of the BCR ([@bib1]; [@bib20]). This allows recruitment of the Syk tyrosine kinase to the BCR, which nucleates the formation of a 'microsignalosome', a microcluster-based signaling complex that includes the Btk tyrosine kinase, phospholipase Cγ2 (PLCγ2), and phosphoinositide 3-kinase (PI3K) ([@bib85]; [@bib93]). BCR signaling stimulates actin polymerization at the periphery of the B cell-APC contact site ([@bib28]), which exerts outward force on the plasma membrane to generate membrane protrusions ([@bib65]). This allows the B cell to scan the APC surface for additional Ag, resulting in further BCR microcluster formation and enhancement of BCR signaling ([@bib28]; [@bib93]).

Subsequent retraction of the B cell membrane is accompanied by the centripetal movement of BCR-Ag microclusters, which coalesce to form the characteristic central supramolecular activation complex (cSMAC) of an immune synapse ([@bib28]). BCR-mediated extraction of Ag from the APC membrane, which allows B cells to present Ags and elicit T cell help, occurs at the cSMAC in naive B cells ([@bib71]; [@bib100]). In T cells, centripetal (i.e. retrograde) actin flow is a driving force for T cell receptor (TCR) microcluster centralization and cSMAC formation ([@bib4]; [@bib40]; [@bib98]). As new actin is polymerized at the cell periphery, the elastic resistance of the plasma membrane causes the peripheral actin network to flow toward the center of the synapse ([@bib75]). Actin dynamics are required for cSMAC formation in B cells ([@bib59]; [@bib87]) but a role for actin retrograde flow has not been established.

Although the actin-dependent formation, movement, and spatial organization of BCR micoclusters are critical for APC-induced B cell activation, the molecular mechanisms that orchestrate this process are not fully understood. Actin organization and dynamics are controlled by a large network of actin-regulatory proteins ([@bib10]; [@bib18]; [@bib64]; [@bib84]). There are two main modes of actin polymerization ([@bib73]). Formin-mediated linear actin polymerization, which is controlled by the RhoA GTPase, generates thin membrane protrusions such as filopodia ([@bib63]). Alternatively, branched actin polymerization is mediated by the 7-subunit actin-related protein (Arp) 2/3 complex, which binds to existing actin filaments and nucleates new filaments that grow at a 70° angle from the mother filament ([@bib36]). Receptor-induced activation of the Cdc42 and Rac GTPases causes conformational changes in nucleation-promoting factors (NPFs) belonging to the Wiskott-Aldrich Syndrome protein (WASp) family, which allows them to activate the Arp2/3 complex ([@bib76]). The Arp2/3 complex nucleates the branched actin networks that underlie the formation of sheet-like membrane protrusions such as lamellipodia ([@bib74]). The peripheral actin network at the T cell immune synapse resembles that of the lamellipodia of migrating cells ([@bib24]; [@bib25]).

A key role for the Arp2/3 complex in T and B cells is suggested by the dysregulated lymphocyte function in patients with Wiskott-Aldrich Syndrome (WAS). WAS is caused by mutations in either WASp or WASp-interacting protein (WIP) ([@bib15]) and is characterized by increased susceptibility to autoimmune disease, recurring infections, and predisposition to lymphomas and leukemias. In B cells, the WASp and N-WASP NPFs, as well as WIP, regulate actin dynamics and BCR signaling at the immune synapse ([@bib51]; [@bib60]; [@bib58]; [@bib94]). Although WASp and N-WASP act upstream of the Arp2/3 complex, the role of Arp2/3 complex-dependent actin dynamics in B cell immune synapse formation and function has not been investigated.

B cell immune synapse formation was first demonstrated in the context of B cell-APC interactions ([@bib6]). However, most subsequent studies have employed Ags that are attached to artificial planar lipid bilayers or to the cytoplasmic face of plasma membrane sheets in order to facilitate imaging of the contact site. We have developed systems for imaging APC-induced B cell immune synapse formation in real time ([@bib92]) and now use this approach to investigate the role of Arp2/3 complex-dependent actin dynamics in B cell immune synapse formation and function. Here, we show that B cells interacting with live, intact APCs form BCR-Ag microclusters within dynamic actin-rich membrane protrusions that are dependent on the Arp2/3 complex. The coalescence of BCR-Ag microclusters into a cSMAC is also dependent on the dynamic branched actin networks that are nucleated by the Arp2/3 complex. Importantly, we show that Arp2/3 complex activity amplifies BCR signaling and is required for maximal B cell activation and proliferation.

Results {#s2}
=======

B cells generate dynamic actin-rich protrusions to scan for Ags on APCs {#s2-1}
-----------------------------------------------------------------------

To visualize how B cells scan the surface of APCs to search for Ag, we generated APCs expressing a fluorescently tagged, transmembrane form of hen egg lysozyme (mHEL-HaloTag) and then imaged the B cell-APC contact site in real time ([Figure 1A](#fig1){ref-type="fig"}). When A20 murine B-lymphoma cells expressing the HEL-specific D1.3 transgenic BCR (A20 D1.3 B cells) were added to the APCs, they rapidly formed BCR-Ag microclusters throughout the contact site. Microclusters that formed at the periphery moved centripetally. Closer to the center of the contact site, microclusters coalesced with each other such that a cSMAC developed within \~10 min ([Figure 1B](#fig1){ref-type="fig"}). Although some BCR-Ag microclusters formed quite far from the center of the contact site ([Figure 1B](#fig1){ref-type="fig"} \[yellow arrowheads\]), nearly all the microclusters coalesced into the cSMAC after 10 min ([Figure 1B](#fig1){ref-type="fig"}, [Video 1](#video1){ref-type="video"}).

![B cells generate dynamic actin-based probing protrusions in response to APC-bound Ags.\
(**A**) Schematic of the B cell-APC system. COS-7 cells expressing mHEL-HaloTag Ag act as APCs for B cells expressing HEL-specific BCRs. (**B**) A20 D1.3 B cells were added to COS-7 cells expressing mHEL-HaloTag and the B cell-APC contact site was imaged every 12 s for 14 min using spinning disk microscopy. Images from [Video 1](#video1){ref-type="video"} are shown. Yellow arrowheads indicate BCR-Ag microclusters that formed far from the center of the contact site. The data are representative of \>40 cells from nine independent experiments. Times are shown in min:s. (**C**) A20 D1.3 B cells expressing F-Tractin-GFP (green) were added to COS-7 APCs expressing mHEL-HaloTag (red) and the B cell-APC contact site was imaged every 6.6 s for 4 min using ISIM. Images from [Video 2](#video2){ref-type="video"} are shown. The different colored arrowheads in the upper panels (actin channel) represent membrane protrusions that were extended or retracted. The yellow circles in the lower panels indicate BCR-Ag microclusters (red) that were formed on new actin protrusions. (**D**) For each frame of [Video 2](#video2){ref-type="video"}, the cell edge, as defined by F-actin, was overlaid as a temporally-coded time series (left). The total area searched by the B cell over the 4-min period of observation is shown on the right. (**E**) Kymographs showing the time evolution of fluorescence signals along the yellow lines in the lower right panel of (**C**) depict the centripetal movement of Ag clusters and the surrounding actin structures. The velocity of a particle is proportional to the angle at which its track deviates from a vertical line along the time axis. See [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} for additional explanation of kymograph analysis. (**F**) A20 B cells expressing F-Tractin-GFP were added to anti-IgG-coated coverslips and the contact site was imaged every 2 s for 10 min using a Zeiss Airyscan microscope. Images from [Video 3](#video3){ref-type="video"} are shown. Blue arrowheads represent a long-lived membrane protrusion. (**G**) A temporally coded time series representing the edge of the cell (left) was generated from [Video 3](#video3){ref-type="video"} and the total area searched by the B cell over the 10 min period of observation is shown (right). Scale bars: 5 µm.](elife-44574-fig1){#fig1}

###### BCR-Ag microclusters coalesce into a cSMAC at the B cell-APC contact site.

A20 D1.3 B cells were added to COS-7 APCs expressing mHEL-GFP (white) and the B cell-APC contact site was imaged using spinning disk microscopy. Images taken every 12 s. Video playback is 10 frames per second (120X real speed). See also [Figure 1B](#fig1){ref-type="fig"}.

10.7554/eLife.44574.004

Membrane protrusions are generally driven by actin polymerization. To image how B cells probe the surface of APCs, we expressed the F-actin-binding protein F-Tractin-GFP in A20 D1.3 B cells and imaged their interaction with mHEL-HaloTag-expressing APCs using instant structured illumination microscopy (ISIM) ([@bib99]) to obtain high spatiotemporal resolution. We found that B cells continually extended and retracted short-lived actin-rich protrusions across the surface of the APC ([Figure 1C](#fig1){ref-type="fig"} \[colored arrowheads\], [Figure 1D](#fig1){ref-type="fig"}, [Video 2](#video2){ref-type="video"}), resulting in an asymmetrical cell shape. This dynamic searching mechanism allowed A20 D1.3 B cells to scan a total area of \~100 µm^2^ on the surface of the APC over 4 min of contact and gather Ag into microclusters ([Figure 1D](#fig1){ref-type="fig"}). BCR-Ag microclusters formed within actin-rich regions, including newly formed protrusions ([Figure 1C](#fig1){ref-type="fig"}, [Video 2](#video2){ref-type="video"}). These microclusters moved toward the center of the synapse along with the actin structures in which they were embedded, especially as membrane protrusions were retracted ([Figure 1E](#fig1){ref-type="fig"}, [Video 2](#video2){ref-type="video"}). As determined from the kymographs in [Figure 1E](#fig1){ref-type="fig"}, the velocities at which the peripheral F-actin structures and BCR-Ag microclusters moved toward the center of the synapse were similar, suggesting that actin dynamics drive the initial centripetal movement of these microclusters. At the same time, F-actin was cleared from the center of the contact site and BCR microclusters within this region coalesced with each other until a cSMAC was formed.

###### Dynamic actin-based protrusions and BCR-Ag microclusters at the B cell-APC contact site.

A20 D1.3 B cells expressing F-Tractin-GFP (green) were added to COS-7 APCs expressing mHEL-HaloTag (red) and the B cell-APC contact site was imaged using ISIM. Images taken every 6.6 s. Video playback is 10 frames per second (66X real speed). See also [Figure 1C](#fig1){ref-type="fig"}.

10.7554/eLife.44574.005

In contrast to their behavior on APCs, B cells exhibited largely radial spreading when they contacted immobilized anti-IgG antibodies (an Ag surrogate) on a rigid glass coverslip ([Figure 1F](#fig1){ref-type="fig"}, [Video 3](#video3){ref-type="video"}). The cells underwent continual outward spreading, reaching a contact area of \~150 µm^2^ after 10 min ([Figure 1G](#fig1){ref-type="fig"}; see also Figure 3C,D). B cells spreading on immobilized anti-Ig formed multiple large lamellipodia, some of which persisted for up to 10 min (for example, [Figure 1F](#fig1){ref-type="fig"} \[blue arrowheads\]). They also formed short dynamic filopodia, many of which were retracted or engulfed by newly formed lamellipodia.

###### Actin dynamics in B cells spreading on immobilized anti-IgG antibodies.

A20 B cells expressing F-Tractin-GFP were added to anti-IgG-coated coverslips and the contact site was imaged using a Zeiss Airyscan microscope. Images taken every 2 s. Video playback is 15 frames per second (30X real speed). See also [Figure 1F](#fig1){ref-type="fig"}.

10.7554/eLife.44574.006

The Arp2/3 complex is required for centralization of BCR-Ag microclusters {#s2-2}
-------------------------------------------------------------------------

The Arp2/3 complex nucleates branched actin polymerization, which drives the formation of lamellipodial protrusions, resembling those that were observed in B cells spreading on APCs ([Figure 1C](#fig1){ref-type="fig"}). Because peripheral actin polymerization is associated with actin retrograde flow, we asked whether Arp2/3 complex activity is required for the centralization of BCR-Ag microclusters. To address this question, we used two complementary and well-characterized approaches to ablate the function of the Arp2/3 complex in B cells. First, we used siRNA to deplete Arp3 expression. Depletion of Arp3 was accompanied by reduced expression of Arp2 and p34, suggesting destabilization of the Arp2/3 complex ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), as observed previously ([@bib70]; [@bib101]). Second, we inhibited Arp2/3 complex activity using a pharmacological inhibitor, CK-666 ([@bib44]). CK-666 locks the Arp2/3 complex in an open conformation, which prevents it from binding to existing actin filaments and nucleating the formation of new actin filaments. B cells treated with CK-666 did not exhibit increased cell death compared to controls ([Figure 2---figure supplement 2A,B](#fig2s2){ref-type="fig"}). Although the COS-7 APCs would also be exposed to CK-666 in these experiments, the CK-666 concentration that we used did not alter their F-actin organization or dynamics over a 30 min timescale ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}).

![Arp2/3 complex function is important for centralization of BCR-Ag microclusters.\
(**A,B**) A20 D1.3 B cells were transfected with control siRNA or Arp3 siRNA (**A**) or pre-treated for 1 hr with 100 μM of either the control compound CK-689 or the Arp2/3 complex inhibitor CK-666 (**B**). The cells were then added to mHEL-GFP-expressing COS-7 APCs and the B cell-APC contact site was imaged every 12 s for 10 min by spinning disk microscopy. Images are from [Video 4](#video4){ref-type="video"} (Control siRNA) and [Video 5](#video5){ref-type="video"} (Arp3 siRNA) or [Video 6](#video6){ref-type="video"} (CK-689) and [Video 7](#video7){ref-type="video"} (CK-666). The percent of cells for which \>90% of the total Ag fluorescence intensity was contained in one or two clusters is graphed. n \> 35 cells from four independent experiments combined (**A**); n \> 18 cells from three independent experiments combined (**B**). (**C,D**) For the control siRNA- and Arp3 siRNA-transfected cells in (**A**), or the CK-689- and CK-666-treated cells in (**B**), binary representations of the Ag clusters present after 10 min of APC contact are shown. The graphs depict the percent of the total Ag fluorescence intensity, in arbitrary units (AU), present in individual clusters. The numbers to the right are the total number of Ag clusters at 10 min. (**E,F**) Control siRNA- and Arp3 siRNA-transfected A20 D1.3 B cells (**E**) or CK-689- and CK-666-treated A20 D1.3 B cells (**F**), were added to mHEL-GFP-expressing COS-7 APCs and imaged every 12 s for 14 min by spinning disk microscopy. For each B cell, the average size of the BCR-Ag microclusters was determined for every frame in the video. The data are plotted as the mean (line) ± SEM (shaded area). In (**E**), n = 35 cells (control) or 48 cells (Arp3 siRNA) from four experiments. In (**F**), n = 18 cells (CK-689) or 20 cells (CK-666) from three experiments. The Mann-Whitney U test was used to calculate p values. \*\*\*\*p\<0.0001; \*\*\*p\<0.001; \*\*p\<0.01; \*p\<0.05. Scale bars: 5 µm.](elife-44574-fig2){#fig2}

We found that inhibiting or depleting the Arp2/3 complex greatly reduced the coalescence of BCR-Ag microclusters into a cSMAC ([Figure 2A,B](#fig2){ref-type="fig"}), even though there was no change in the total amount of Ag that was gathered into microclusters ([Figure 2---figure supplement 4A,B](#fig2s4){ref-type="fig"}) or the number of BCR-Ag microclusters that formed ([Figure 2---figure supplement 4C,D](#fig2s4){ref-type="fig"}). In A20 D1.3 B cells that were transfected with control siRNA ([Figure 2A](#fig2){ref-type="fig"}, [Video 4](#video4){ref-type="video"}) or treated with CK-689 ([Figure 2B](#fig2){ref-type="fig"}, [Video 6](#video6){ref-type="video"}), an inactive analog of CK-666, BCR-Ag microclusters exhibited obvious centripetal movement. By 10 min after contacting the APCs, \~60% of the B cells had gathered \>90% of the Ag fluorescence into one or two large clusters at the center of the synapse, which we define as having formed a cSMAC ([Figure 2A,B](#fig2){ref-type="fig"}). By contrast, many of the BCR-Ag microclusters in the Arp3 siRNA-expressing cells ([Figure 2A](#fig2){ref-type="fig"}, [Video 5](#video5){ref-type="video"}) and the CK-666-treated cells ([Figure 2B](#fig2){ref-type="fig"}, [Video 7](#video7){ref-type="video"}) did not exhibit persistent centripetal motion and only \~15% of the cells in which the Arp2/3 complex was inhibited or depleted formed a cSMAC by 10 min ([Figure 2A,B](#fig2){ref-type="fig"}). Even after 30 min, very few CK-666-treated cells formed a cSMAC (data not shown).

###### BCR-Ag microclusters coalesce into a cSMAC in B cells expressing control siRNA.

A20 D1.3 B cells expressing control siRNA were added to COS-7 APCs expressing mHEL-GFP (white) and the B cell-APC contact site was imaged using spinning disk microscopy. Images taken every 12 s. Video playback is 10 frames per second (120X real speed). Four representative cells are shown. The first cell in the video is also shown in [Figure 2A](#fig2){ref-type="fig"}. DOI: <https://doi.org/10.5061/dryad.3b15k/2>

10.7554/eLife.44574.013

###### Impaired cSMAC formation in B cells expressing Arp3 siRNA.

A20 D1.3 B cells expressing Arp3 siRNA were added to COS-7 APCs expressing mHEL-GFP (white) and the B cell-APC contact site was imaged using spinning disk microscopy. Images taken every 12 s. The video is played back at 10 frames per second (120X real speed). Four representative cells are shown. The first cell in the video is also shown in [Figure 2A](#fig2){ref-type="fig"}. DOI: <https://doi.org/10.5061/dryad.3bc215k/1>

10.7554/eLife.44574.014

###### BCR-Ag microclusters coalesce into a cSMAC in CK-689-treated B cells.

A20 D1.3 B cells were pre-treated with 100 µM CK-689 for 1 hr and then added to COS-7 APCs expressing mHEL-GFP (white). The B cell-APC contact site was imaged using spinning disk microscopy. Images taken every 12 s. Video playback is 10 frames per second (120X real speed). Four representative cells are shown. The first cell in the video is also shown in [Figure 2B](#fig2){ref-type="fig"}. DOI: <https://doi.org/10.5061/dryad.3bc215k/3>

10.7554/eLife.44574.015

###### Impaired cSMAC formation in CK-666-treated B cells.

A20 D1.3 B cells were pre-treated with 100 µM CK-666 for 1 hr and then added to COS-7 APCs expressing mHEL-GFP (white). The B cell-APC contact site was imaged using spinning disk microscopy. Images taken every 12 s. Video playback is 10 frames per second (120X real speed). Four representative cells are shown. The first cell in the video is also shown in [Figure 2B](#fig2){ref-type="fig"}. DOI: <https://doi.org/10.5061/dryad.3bc215k/4>

10.7554/eLife.44574.016

The extent of BCR-Ag microcluster coalescence and cSMAC formation was further analyzed by quantifying the distance of each microcluster on an individual B cell from the center of mass of the Ag fluorescence (i.e. the center of the immune synapse). For each B cell, the average microcluster distance was calculated for each frame in the video and this value was normalized to the maximum average distance for that cell ([Figure 2---figure supplement 4E,F](#fig2s4){ref-type="fig"}). In A20 D1.3 B cells that were transfected with control siRNA or treated with CK-689, the normalized average distance from the center decreased over time, indicating that microclusters moved towards the center of the immune synapse. This can be seen in kymographs depicting microclusters moving centripetally from the cell periphery and merging with other microclusters at the center of the immune synapse in [Figure 2---figure supplement 4G,H](#fig2s4){ref-type="fig"}. However, in Arp3 siRNA-transfected and CK-666-treated A20 D1.3 B cells, the average distance of BCR microclusters from the center of the synapse remained relatively unchanged over the entire 14 min imaging period. This is reflected in the kymoraphs in [Figure 2---figure supplement 4G,H](#fig2s4){ref-type="fig"}. To assess cSMAC formation, the distribution of Ag fluorescence into clusters over time was quantified. Cumulative frequency distribution curves showed that the 50th percentile (cumulative frequency = 0.5) for the number of clusters per cell required to contain 90% of the Ag fluorescence after 10 min of B cell-APC contact was \~1 for the control siRNA-transfected A20 D1.3 B cells and CK-689-treated cells versus four for the Arp3 siRNA-transfected cells and CK-666-treated cells ([Figure 2---figure supplement 4I,J](#fig2s4){ref-type="fig"}). For example, after 10 min of contact with an APC, the control siRNA-transfected B cell shown in [Figure 2A](#fig2){ref-type="fig"} had coalesced all of the Ag into four clusters, one of which contained 97.7% of the Ag fluorescence ([Figure 2C](#fig2){ref-type="fig"}). By contrast, a similar amount of Ag was distributed among 16 distinct clusters in the Arp3 siRNA-transfected cell depicted in [Figure 2A](#fig2){ref-type="fig"}, and no individual cluster contained more than 43% of the total Ag fluorescence ([Figure 2C](#fig2){ref-type="fig"}). Similar results were obtained when comparing the CK-689-treated (control) and CK-666-treated cells from [Figure 2B](#fig2){ref-type="fig"} ([Figure 2D](#fig2){ref-type="fig"}). Again, the control cell formed a cSMAC into which \~ 95% of the Ag was gathered whereas no cluster in the CK-666-treated cells contained more than 22% of the Ag fluorescence. For all B cells analyzed in this manner, the number of BCR-Ag microclusters formed after 10 min in contact with an APC, as well as the distribution of the total Ag fluorescence among individual clusters, is shown in [Figure 2---figure supplement 5](#fig2s5){ref-type="fig"}.

The failure to form a cSMAC when the Arp2/3 complex is depleted or inhibited was due to decreased merger of individual BCR microclusters into larger clusters. Consistent with this idea, the average size of BCR-Ag microclusters increased steadily over time in control cells as the microclusters merged but remained relatively unchanged over the 14 min of imaging in the Arp3 siRNA-treated cells and CK-666-treated cells ([Figure 2E,F](#fig2){ref-type="fig"}). Consequently, because microclusters merged, the number of individual microclusters per cell decreased over time in the control cells but remained similar, or increased, when Arp2/3 complex activity was inhibited ([Figure 2---figure supplement 4C,D](#fig2s4){ref-type="fig"}). Thus, BCR-mediated gathering of APC-bound Ags into a cSMAC at the center of the synapse is strongly dependent on the functions of the Arp2/3 complex.

The Arp2/3 complex is important for BCR-induced actin reorganization and dynamics {#s2-3}
---------------------------------------------------------------------------------

To understand how the Arp2/3 complex promotes BCR microcluster centralization and cSMAC formation, we sought to define its role in actin organization and dynamics at the contact site between a B cell and an Ag-bearing surface. Ags or anti-Ig antibodies that are immobilized on coverslips are widely used model systems for imaging BCR-induced spreading and actin reorganization with high resolution. To assess the role of the Arp 2/3 complex in this response, we used stimulated emission depletion (STED) microscopy. A20 B cells that bound to anti-IgG coated coverslips extended broad lamellipodia and exhibited radial spreading (control siRNA cells in [Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, CK-689-treated cells in [Figure 3B](#fig3){ref-type="fig"}). This cell morphology was characterized by a dense peripheral ring of highly branched F-actin surrounding an actin-depleted central area that contained thin actin filaments ([Figure 3A,B](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Within the peripheral branched actin network of the lamellipodia, linear actin filaments, which may be nucleated by formins, extended perpendicularly from the edge of the cell to the inner face of the peripheral actin ring ([Figure 3A,B](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"} \[yellow arrowheads\]). We also observed long, linear actin filaments that formed actin arcs running parallel to the inner face of the peripheral ring of branched actin ([Figure 3B](#fig3){ref-type="fig"} \[green arrowheads\]; [Figure 3E](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}), which were associated with myosin IIA ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). These are similar to the actomyosin arcs that have been described in T cells ([@bib68]).

![The Arp2/3 complex is important for BCR-induced actin reorganization and dynamics.\
(**A,B**) A20 B cells were transfected with either control siRNA or Arp3 siRNA (**A**) or pre-treated for 1 hr with 100 μM of the control compound CK-689 or the Arp2/3 complex inhibitor CK-666 (**B**). Cells were then allowed to spread on anti-IgG-coated coverslips for the indicated times before being fixed, stained for actin, and imaged by STED microscopy. Images representative of \>20 cells per condition are shown. Yellow arrowheads indicate linear actin structures embedded within the peripheral branched actin network. Green arrowheads indicate actin arcs. Scale bars: 5 µm. For the regions within the yellow boxes, the images were enlarged (scale bars: 2 µm) and the relative densities of the actin structures are shown as heat maps. (**C,D**) A20 B cells were transfected with either control siRNA or Arp3 siRNA (**C**) or pre-treated for 1 hr with μM CK-689 or CK-666 (**D**). The cells were then allowed to spread on anti-IgG-coated coverslips for the indicated times before being stained for F-actin. The B cell-coverslip contact site was imaged using spinning disk microscopy. The cell area was quantified, using F-actin to define the cell edge. For each data point the mean ± SEM is shown for \>27 cells from a representative experiment. \*\*\*\*p\<0.0001; \*\*p\<0.01; \*p\<0.05; ns, not significant; Mann-Whitney U test. (**E**) A20 B cells expressing F-Tractin-GFP were pre-treated for 1 hr with CK-689 or CK-666 and then added to anti-IgG-coated chamber wells. After 5 min, the cells were imaged by TIRF-SIM at 1 s intervals for 1 min. The left panels are the first images from [Video 8](#video8){ref-type="video"} (CK-689-treated cells) and [Video 9](#video9){ref-type="video"} (CK-689-treated cells), respectively (Scale bars: 5 µm). Yellow arrowheads indicate linear actin structures embedded within the peripheral branched actin network. Green arrowheads indicate actin arcs. The middle panels are enlargements of the areas within the yellow boxes in the left panels (Scale bars: 2 µm). The right panels are kymographs along the yellow dotted lines in the middle panels.](elife-44574-fig3){#fig3}

###### Peripheral actin dynamics in CK-689-treated B cells plated on immobilized anti-IgG.

A20 B cells expressing F-Tractin-GFP were pre-treated for 1 hr with 100 µM CK-689 and then added to anti-IgG-coated coverslips. The contact site was imaged using TIRF-SIM. Images taken every 1 s. Video playback is 10 frames per second (10X real speed). See also [Figure 3E](#fig3){ref-type="fig"}.

10.7554/eLife.44574.019

###### Impaired peripheral actin dynamics in CK-666-treated B cells plated on immobilized anti-IgG.

A20 B cells expressing F-Tractin-GFP were pre-treated for 1 hr with 100 µM CK-666 and then added to anti-IgG-coated coverslips. The contact site was imaged using TIRF-SIM. Images taken every 1 s. Video playback is 10 frames per second (10X real speed). See also [Figure 3E](#fig3){ref-type="fig"}.

10.7554/eLife.44574.020

This actin organization at the Ag contact site was strongly dependent on Arp2/3 complex activity. When we depleted Arp3 with siRNA ([Figure 3A](#fig3){ref-type="fig"}), or inhibited the Arp2/3 complex in A20 B cells using CK-666 ([Figure 3B](#fig3){ref-type="fig"}), BCR-induced spreading and actin reorganization were dramatically altered. Unlike the control A20 B cells, which formed a highly dense, sheet-like actin network at the periphery, Arp3-depleted and CK-666-treated B cells extended long and loosely packed filopodia-like fibers ([Figure 3A,B](#fig3){ref-type="fig"}). This aberrant actin reorganization resulted in substantially reduced cell spreading on anti-IgG-coated coverslips ([Figure 3C,D](#fig3){ref-type="fig"}).

Because branched actin structures that are nucleated by the Arp2/3 complex exert forces on the plasma membrane, we hypothesized that retrograde flow of actin would be disrupted in B cells treated with the Arp2/3 inhibitor. To test this, A20 B cells expressing F-tractin-GFP were treated with CK-689 or CK-666 and then added to anti-IgG-coated coverslips. Total internal reflection fluorescence structured illumination microscopy (TIRF-SIM) was used to image actin dynamics with high spatial and temporal resolution. In control CK-689-treated cells, the F-actin networks were highly dynamic at the cell edge, with actin retrograde flow rates of \~2.5 µm/min ([Figure 3E](#fig3){ref-type="fig"}, [Video 8](#video8){ref-type="video"}). In contrast, in B cells treated with the Arp2/3 complex inhibitor, the peripheral actin structures were nearly static ([Figure 3](#fig3){ref-type="fig"}, [Video 9](#video9){ref-type="video"}). Thus, Arp2/3 complex function is essential for BCR-induced actin reorganization and for peripheral actin dynamics.

Arp2/3 complex-dependent actin dynamics and membrane retraction drive BCR microcluster centralization {#s2-4}
-----------------------------------------------------------------------------------------------------

How specific actin architectures allow B cells to scan APC membranes and then centralize the resulting BCR microclusters into a cSMAC is not known. To test the role of Arp2/3-nucleated actin networks in these processes, we used ISIM to simultaneously image actin structures and BCR-Ag microclusters in F-Tractin-GFP-transfected A20 D1.3 B cells interacting with mHEL-HaloTag-expressing COS-7 cells. As shown in [Video 2](#video2){ref-type="video"} and [Video 10](#video10){ref-type="video"}, control B cells extended dynamic, transient actin-rich protrusions over the surface of the APC, with both lamellipodial and filopodia-like structures being observed (see also [Figure 4A](#fig4){ref-type="fig"}, [Figure 5A](#fig5){ref-type="fig"}). Moreover, the high spatiotemporal resolution of ISIM revealed that BCR-Ag microclusters were embedded within actin-rich protrusions and moved toward the cell body as these protrusions were retracted ([Figure 4A](#fig4){ref-type="fig"}, [Figure 5A](#fig5){ref-type="fig"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}, [Video 10](#video10){ref-type="video"}; see also [Figure 1C](#fig1){ref-type="fig"}). For example, the microcluster highlighted in [Figure 5A](#fig5){ref-type="fig"} is encaged within an actin-rich protrusion. In contrast, B cells that were treated with the Arp2/3 complex inhibitor CK-666 primarily extended long, linear, filopodia-like actin structures over the surface of the APC ([Figure 4A](#fig4){ref-type="fig"}, [Figure 5A](#fig5){ref-type="fig"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}, [Video 11](#video11){ref-type="video"}). Most of these actin structures did not retract toward the cell body over the 6.5 min observation period. Moreover, BCR-Ag microclusters that formed on these protrusions did not translocate toward the center of the synapse or merge with other microclusters ([Figure 4A](#fig4){ref-type="fig"}, [Figure 5A](#fig5){ref-type="fig"}, [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}, [Video 11](#video11){ref-type="video"}).

![The Arp2/3 complex is important for actin and BCR microcluster dynamics at the B cell-APC immune synapse.\
(**A--C**) A20 D1.3 B cells expressing F-Tractin-GFP (green) were pre-treated with 100 µM CK-689 or CK-666 for 1 hr and then added to COS-7 cells expressing mHEL-HaloTag (red). The cells were imaged every 6.6 s for 6 min using ISIM. Images from [Video 10](#video10){ref-type="video"} and [Video 11](#video11){ref-type="video"} are shown in (**A**). Arrowheads indicate new protrusion events. The yellow boxes indicate the regions that are enlarged in [Figure 5](#fig5){ref-type="fig"}. In (**B**) the cell edge from each frame in [Video 10](#video10){ref-type="video"} (CK-689-treated cells) or [Video 11](#video11){ref-type="video"} (CK-666-treated cells), as defined by the peripheral F-actin, was overlaid as a temporally coded time series (left). The total area searched by the B cell over the 6-min period of observation is shown the right. In (**C**) the B cell-APC contact area is shown as a function of time for the cells in (**A**) (solid lines), and for another set of representative cells (dashed lines; images are shown in [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). (**D,E**) A20 D1.3 B cells expressing F-Tractin-GFP (green) were pre-treated with 100 μM CK-689 or CK-666 and then added to COS-7 cells expressing mHEL-HaloTag (red). The cells were fixed at the indicated times and imaged by spinning disk microscopy. Representative images are shown (**D**) and the B cell-APC contact area (mean ± SEM), as defined by F-actin, is graphed (**E**). For each data point, n \> 20 cells from three independent experiments except for the 1 min time point (n = 4 cells). ns, not significant (p=0.7219, p=0.1310, p=0.0722, p=0.1443, p=0.2930, p=0.6263 for the 1, 3, 5, 10, 15, and 30 min time points, respectively); two-tailed paired t-test. Scale bars: 5 µm.](elife-44574-fig4){#fig4}

![Arp2/3 complex-dependent actin structures encage BCR-Ag microclusters on membrane protrusions.\
(**A**) Images from [Video 10](#video10){ref-type="video"} and [Video 11](#video11){ref-type="video"} showing enlargements of the regions indicated by the yellow boxes in [Figure 4](#fig4){ref-type="fig"}. A20 D1.3 B cells expressing F-Tractin-GFP (green) were pre-treated with 100 μM CK-689 or CK-666 for 1 hr and then added to COS-7 cells expressing mHEL-HaloTag (red). The cells were imaged every 6.6 s for 6 min using ISIM. Scale bars: 2 µm. (**B**) The kymographs represent a time series of images taken along the white dashed lines in (**A**).](elife-44574-fig5){#fig5}

###### Actin and BCR-Ag microcluster dynamics in CK-689-treated B cells interacting with APCs.

A20 D1.3 B cells expressing F-Tractin-GFP (green) were pre-treated for 1 hr with 100 µM CK-689 and then added to COS-7 APCs expressing mHEL-HaloTag (red). The B cell-APC contact site was imaged using ISIM. Images taken every 6.6 s. Video playback is 10 frames per second (66X real speed). See also [Figure 4](#fig4){ref-type="fig"} and [Figure 5](#fig5){ref-type="fig"}.

10.7554/eLife.44574.024

###### Impaired actin and BCR-Ag microcluster dynamics in CK-666-treated B cells interacting with APCs.

A20 D1.3 B cells expressing F-Tractin-GFP (green) were pre-treated for 1 hr with 100 µM CK-666 and then added to COS-7 APCs expressing mHEL-HaloTag (red). The B cell-APC contact site was imaged using ISIM. Images taken every 6.6 s. Video playback is 10 frames per second (66X real speed). See also [Figure 4](#fig4){ref-type="fig"} and [Figure 5](#fig5){ref-type="fig"}.

10.7554/eLife.44574.025

Although the architectures of the actin protrusions generated by control and CK-666-treated cells were dramatically different, the cells explored roughly the same area of the APC surface over the period of observation ([Figure 4B--E](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). This is in contrast to the significantly reduced cell spreading on rigid anti-Ig-coated surfaces that was observed when the Arp2/3 complex was depleted or inhibited ([Figure 3](#fig3){ref-type="fig"}). Thus, Arp2/3 complex activity is requred for B cells to spread on rigid surfaces but may be dispensable for B cells to effectively probe the APC surface and form BCR-Ag microclusters under the conditions tested. However, Arp2/3 complex-mediated actin polymerization, and the resulting actin retrograde flow, appears to be essential for the centralization of BCR-Ag microclusters. Consistent with this idea, kymograph analysis showed that peripheral BCR-Ag clusters in control cells moved toward the center of the synapse together with, and at a similar velocity as, the surrounding actin structures ([Figure 5B](#fig5){ref-type="fig"}, [Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}). In contrast, when the Arp2/3 complex was inhibited, both the BCR-Ag clusters and the associated actin structures were relatively immobile ([Figure 5B](#fig5){ref-type="fig"}, [Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}). Taken together, these data suggest that Arp2/3 complex-dependent actin structures encage BCR-Ag microclusters, such that the actin retrograde flow drives their initial centripetal movement. This appears to be required for the subsequent formation of a cSMAC, which occurs in the actin-depleted central region of the cell.

Arp2/3 complex activity amplifies BCR signaling at the immune synapse {#s2-5}
---------------------------------------------------------------------

How the spatial organization of the BCR at the immune synapse impacts BCR signaling and B cell activation is not fully understood. Because inhibition of the Arp2/3 complex prevented the centripetal movement of BCR microclusters into a cSMAC but did not significantly alter the amount of Ag gathered into BCR microclusters ([Figure 2C](#fig2){ref-type="fig"}, [Figure 2---figure supplement 4A,B](#fig2s4){ref-type="fig"}, [Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}), this allowed us to ask whether the Arp2/3 complex-dependent spatial patterning of BCR-Ag microclusters impacts BCR signaling output. We quantified proximal BCR signaling events at the contact site between ex vivo primary murine splenic B cells and COS-7 APCs expressing a single-chain anti-Ig$\kappa$ surrogate Ag on their surface ([@bib29]). A critical initial step in BCR signaling is phosphorylation of the tyrosine residues within the immunoreceptor tyrosine-based activation motifs (ITAMs) present in the CD79a/b signaling subunit of the BCR ([@bib20]). This is required for the recruitment and activation of Syk, a tyrosine kinase that phosphorylates multiple proteins that are critical for BCR signaling and B cell activation.

APC-induced phosphorylation of CD79a/b at the immune synapse was assessed by staining with an antibody that recognizes the phosphorylated ITAMs of both CD79a and CD79b. We found that CD79 phosphorylation occurred rapidly at the B cell-APC contact site and co-localized with BCR-Ag clusters, which were detected using an antibody that detects the surrogate Ag ([Figure 6A](#fig6){ref-type="fig"}). As shown in [Figure 2](#fig2){ref-type="fig"}, the BCR-Ag microcluster coalesced into a tight cSMAC within 5--10 min in control cells but not in B cells treated with the Arp2/3 complex inhibitor CK-666 ([Figure 6A](#fig6){ref-type="fig"}). Using quantitative image analysis, we then determined the relationship between the amount of Ag gathered into clusters and the signaling output at those BCR-Ag microclusters. For each B cell, the total phospho-CD79 (pCD79) or phospho-Syk (pSyk) fluorescence intensity present in clusters at the B cell-APC interface was divided by the total fluorescence intensity of clustered Ag. In control B cells treated with CK-689, pCD79 levels were maximal at 5 and 10 min after the B cells were added to the APCs and declined thereafter ([Figure 6B](#fig6){ref-type="fig"}), perhaps due to the internalization of BCR-Ag microclusters. Importantly, B cells treated with the Arp2/3 complex inhibitor exhibited significantly lower pCD79 levels at the 5, 10, and 15 min time points compared to control cells ([Figure 6B](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}). Similar results were obtained when HEL-specific B cells from MD4 mice were added to COS-7 APCs expressing the HEL-HaloTag Ag ([Figure 6---figure supplement 1C,D](#fig6s1){ref-type="fig"}).

![The Arp2/3 complex amplifies proximal BCR signaling.\
(**A,B**) Primary murine B cells were pre-treated with 100 μM CK-689 or CK-666 for 1 hr and then added to COS-7 cells expressing the single-chain anti-Ig$\kappa$ surrogate Ag. The cells were fixed at the indicated times and stained with an antibody that recognizes the surrogate Ag and with an antibody that recognizes the phosphorylated ITAMs in CD79a and CD79b (pCD79). Images of representative cells are shown (**A**). For each B cell, the total fluorescence intensity of clustered pCD79 was divided by the total fluorescence intensity of clustered Ag at the B cell-APC contact site. Beeswarm plots in which each dot is one cell. The median (red line) and interquartile ranges (red box) for \>39 cells for each time point from a representative experiment are shown (**B**). (**C,D**) Primary murine B cells were pre-treated with 100 μM CK-689 or CK-666 for 1 hr and then added to COS-7 cells expressing the single-chain anti-Ig$\kappa$ surrogate Ag (**C**) or stimulated with 10 µg/ml soluble anti-Ig$\kappa$ (**D**) for the indicated times. pCD79 and total CD79a immunoblots are shown (left panels) and the pCD79/total CD79a ratios are graphed (right panels). Dotted red line corresponds to the pCD79/total CD79a ratio value for unstimulated CK-689-treated B cells. Representative data from one of seven experiments. An additional independent experiment is shown in [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}. See [Figure 9---figure supplement 6](#fig9s6){ref-type="fig"} for full blots. (**E,F**) Primary murine B cells that had been pre-treated with 100 μM CK-689 or CK-666 for 1 hr were added to COS-7 cells expressing the single-chain anti-Ig$\kappa$ Ag. The cells were fixed at the indicated times and stained for the surrogate Ag and pSyk (**E**). For each B cell, the total fluorescence intensity of clustered pSyk was divided by the total fluorescence intensity of clustered Ag at the B cell-APC contact site. Beeswarm plots with the median and interquartile ranges for \>112 cells for each time point from a representative experiment are shown (**F**). \*\*\*\*p\<0.0001; \*\*\*p\<0.001; \*\*p\<0.01; \*p\<0.05; ns, not significant; Mann-Whitney U test. Scale bars: 2 µm.](elife-44574-fig6){#fig6}

We also analyzed CD79 phosphorylation by immunoblotting, which would detect BCRs on the cell surface as well as ones that have been internalized. Indeed, immunoblotting showed that APC-induced CD79 phosphorylation increased continually over the first 30 min of B cell-APC contact ([Figure 6C](#fig6){ref-type="fig"}). Importantly, similar to what was observed by imaging the B cell-APC interface, treating the B cells with CK-666 reduced APC-induced CD79 phosphorylation, especially at the 15 and 30 min time points ([Figure 6C](#fig6){ref-type="fig"}, [Figure 6---figure supplement 2A](#fig6s2){ref-type="fig"}). In contrast, CK-666 treatment did not impair the ability of soluble anti-Ig antibodies to stimulate CD79 phosphorylation ([Figure 6D](#fig6){ref-type="fig"}, [Figure 6---figure supplement 2B](#fig6s2){ref-type="fig"}). This suggests that the Arp2/3 complex-dependent spatial patterning of BCR-Ag microclusters amplifies proximal BCR signaling in response to polarized, membrane-bound Ags but not soluble Ags.

The Ag-induced binding of Syk to phosphorylated CD79a/b leads to the phosphorylation of Syk ([@bib77]). Phosphorylation on Y342 and Y346 increases Syk activity and generates binding sites for PLCγ2 and Vav ([@bib34]). When ex vivo primary B cells interacted with APCs expressing the single-chain anti-Ig$\kappa$ surrogate Ag, co-localization of pSyk (Y346) with BCR-Ag clusters was observed within 3 min ([Figure 6E](#fig6){ref-type="fig"}, [Figure 6---figure supplement 3A](#fig6s3){ref-type="fig"}). B cells treated with CK-666 had significantly lower levels of pSyk at 3 min and 5 min after contacting the APCs, compared to control cells ([Figure 6F](#fig6){ref-type="fig"}). Similar results were obtained when HEL-specific primary B cells were added to APCs expressing the HEL-HaloTag Ag ([Figure 6---figure supplement 3B,C](#fig6s3){ref-type="fig"}). Together, these data suggest that the Arp2/3 complex is required for the amplification of the earliest BCR signaling events, phosphorylation of the CD79a/b ITAMs and phosphorylation of tyrosine residues in Syk that are required for its activation.

Inhibiting the Arp2/3 complex increases tonic BCR signaling and BCR diffusion {#s2-6}
-----------------------------------------------------------------------------

Although treating B cells with the Arp2/3 complex inhibitor reduced the ability of APC-bound Ags to stimulate the phosphorylation of CD79 and Syk, CK-666-treated B cells exhibited higher levels of pCD79 prior to Ag encounter ([Figure 6C,D](#fig6){ref-type="fig"}; 0 min time point). This was accompanied by increased phosphorylation of ERK and Akt, downstream targets of BCR signaling ([Figure 7A](#fig7){ref-type="fig"}). Actin-based diffusion barriers restrict the lateral mobility of the BCR within the plasma membrane and increased BCR mobility is associated with increased tonic Ag-independent BCR signaling ([@bib30]; [@bib86]). Because Arp2/3 complex activity contributes to the formation of the submembrane cortical actin network, which creates diffusion barriers for transmembrane proteins, we tested the hypothesis that Arp2/3 complex activity limits Ag-independent BCR signaling by restricting BCR mobility prior to Ag encounter. We used single-particle tracking (SPT) to compare the diffusion and confinement properties of both IgM- and IgD-containing BCRs, in control versus CK-666-treated primary B cells. Indeed, the median diffusion coefficients for IgM and IgD were approximately 2.8-fold higher in CK-666-treated cells than in control CK-689-treated cells ([Figure 7B--D](#fig7){ref-type="fig"}). Consistent with their increased lateral mobility, both IgM and IgD had larger effective confinement diameters in CK-666-treated cells than in control CK-689-treated cells ([Figure 7B--D](#fig7){ref-type="fig"}). Thus, CK-666 treatment increases both BCR mobility and tonic BCR signaling. This suggests that the Arp2/3 complex contributes to the formation of actin-based barriers that normally limit BCR diffusion and tonic BCR signaling.

![The Arp2/3 complex regulates BCR mobility and tonic signaling in resting B cells.\
(**A**) Ex vivo primary murine B cells were treated with DMSO, 100 μM CK-689, or 100 μM CK-666 for 1 hr, or stimulated with anti-Ig$\kappa$ antibodies for 5 min. Cell extracts were analyzed by immunoblotting with antibodies against phospho-ERK (pERK) and total ERK, or phospho-Akt (pAkt) and total Akt. Representative blot are shown (left). Band intensities were quantified and the ratio of pERK/total ERK and pAkt/total Akt (right) relative to those in anti-Ig$\kappa$-treated cells (=1.0) are graphed as the mean ± SEM for four (pERK) or five (pAkt) independent experiments. Two-tailed paired t-test. See [Figure 9---figure supplement 6](#fig9s6){ref-type="fig"} for full blots. (**B--D**) Ex vivo primary murine splenic B cells were treated with 100 μM CK-689 or CK-666 for 1 hr. SPT was then carried out by labeling the cells at low stoichiometry with Cy3-labeled Fab fragments of antibodies to IgM (**B**) or IgD (**C**). The cells were then settled onto non-stimulatory anti-MHC II-coated coverslips and imaged for 10 s at 33 Hz by total internal reflection florescence microscopy (TIRFM). Single-particle trajectories from representative cells are plotted using a color-coded temporal scale (left panels). Scale bars: 5 µm. Diffusion coefficients were calculated for the indicated number of tracks and cumulative frequency curves are shown (center panels). The diameter of maximum displacement over the 10 s period of observation (confinement diameter) was calculated for each track and cumulative frequency curves are shown (right panels). The dots on the curves indicate the median values. Representative data from one of three independent experiments \*\*\*\*p\<0.0001; Kolmogorov-Smirnov test.](elife-44574-fig7){#fig7}

Arp2/3 complex activity is important for BCR-CD19 interactions {#s2-7}
--------------------------------------------------------------

CD19 is essential for B cell activation by membrane-bound Ags but not soluble Ags ([@bib23]; [@bib96]). Initial BCR signaling leads to phosphorylation of CD19 on key tyrosine residues, allowing CD19 to recruit PI3K and Vav ([@bib12]; [@bib72]; [@bib88]). CD19 is relatively immobile within the plasma membrane and this facilitates BCR-CD19 interactions and CD19-dependent amplification of BCR signaling ([@bib62]). Indeed, depolymerizing the actin cytoskeleton results in diminished CD19 phosphorylation and PI3K signaling in response to BCR stimulation ([@bib51]; [@bib62]). Using SPT, we found that treating B cells with CK-666 caused a 2.3-fold increase in the median diffusion coefficient for CD19 and increased its effective confinement diameter ([Figure 8A](#fig8){ref-type="fig"}). This suggests that Arp2/3 complex-dependent actin structures limit the lateral mobility of CD19 in the plasma membrane, which may be important for membrane-bound Ags to stimulate CD19 phosphorylation and augment BCR-CD19 interactions.

![The Arp2/3 complex regulates CD19 mobility and BCR-CD19 interactions.\
(**A**) Ex vivo primary murine splenic B cells were treated with 100 μM CK-689 or CK-666 for 1 hr. SPT was then carried out as in [Figure 7](#fig7){ref-type="fig"}, using Cy3-labeled Fab fragments of antibodies to CD19. Single-particle trajectories from a representative cell are plotted using a color-coded temporal scale (left panels). Scale bars: 5 µm. Diffusion coefficients (center panels) and the diameter of maximum displacement (confinement diameter, right panels) over the 10 s period of observation were calculated for each track and cumulative frequency curves are shown. The dots on the curves indicate the median values. \*\*\*\*p\<0.0001; Kolmogorov-Smirnov test. (**B--E**) Primary murine B cells were pre-treated with 100 μM CK-689 or CK-666 for 1 hr and then added to COS-7 cells expressing the single-chain anti-Ig$\kappa$ surrogate Ag. Cells were fixed at the indicated time points and stained with an antibody that recognizes the surrogate Ag and with an antibody that recognizes phosphorylated CD19. Representative cells are shown (**B**). Scale bars: 2 µm. For each B cell, the total fluorescence intensity of clustered pCD19 was calculated. Beeswarm plots in which each dot represents one cell are plotted with the median (red line) and interquartile ranges (red box) for \>125 cells per time point from a representative experiment (**C**). For each cell in (**C**), the fraction of total pCD19 fluorescence that overlaps with BCR-Ag microclusters was quantified by calculating the Manders' coefficient (**D**). For each cell in (**C**), the total fluorescence intensity of pCD19 that was within BCR-Ag microclusters in cells was quantified (**E**). \*\*\*\*p\<0.0001; \*\*\*p\<0.001; ns, not significant; Mann-Whitney U test.](elife-44574-fig8){#fig8}

To test this, we asked whether inhibiting Arp2/3 complex activity altered the ability of membrane-bound Ags to stimulate CD19 phosphorylation. We used phospho-specific antibodies to detect CD19 that is phosphorylated on Y531 (pCD19) and quantified the level of pCD19 at the contact site between primary splenic B cells and APCs expressing the single-chain anti-Ig$\kappa$ surrogate Ag ([Figure 8B,C](#fig8){ref-type="fig"}). We found that the initial peak of APC-induced CD19 phosphorylation was diminished and delayed in CK-666-treated B cells, compared to the control CK-689-treated cells ([Figure 8C](#fig8){ref-type="fig"}, [Figure 8---figure supplement 1A](#fig8s1){ref-type="fig"}). As observed for phosphorylation of CD79, inhibiting the Arp2/3 complex did not impair the ability of soluble anti-Ig antibodies to stimulate rapid and robust CD19 phosphorylation ([Figure 8---figure supplement 1B](#fig8s1){ref-type="fig"}). This suggests that Arp2/3 complex-dependent actin structures provide spatial organization that is important for BCR-induced CD19 phosphorylation in response to spatially restricted membrane-bound Ags.

Because the co-localization of pCD19 with the BCR could determine the extent to which CD19 amplifies BCR signaling, we next quantified the fraction of total pCD19 fluorescence that overlaps BCR-Ag microclusters, using the Manders' coefficient. In control cells, much of the pCD19 fluorescence occured within BCR-Ag clusters at all time points after initiating B cell-APC contact ([Figure 8D](#fig8){ref-type="fig"}). The pCD19-Ag overlap was significantly less in the CK-666-treated B cells than in the control cells at all time points. By contrast, the overlap between pSyk clusters and BCR-Ag clusters in CK-666-treated cells was either not significantly different from, or was slightly higher, than in control cells over the first 15 min of B-APC interactions ([Figure 8---figure supplement 1C](#fig8s1){ref-type="fig"}). Thus, unlike pSyk, which is strongly associated with signaling BCRs, the co-localization of pCD19 with the BCR is impacted by Arp2/3 complex activity. Importantly, we found that the total amount of pCD19 fluorescence that overlapped with BCR-Ag clusters was much lower in CK-666-treated cells than in control cells at the 3-min time point. This reflects both decreased CD19 phosphorylation and decreased BCR-pCD19 overlap in the CK-666-treated cells. As for total pCD19 fluorescence, the initial peak of pCD19 fluorescence within BCR-Ag microclusters was diminished and delayed when Arp2/3 complex activity was inhibited ([Figure 8E](#fig8){ref-type="fig"}). Taken together, these findings indicate that actin networks nucleated by the Arp2/3 complex promote APC-induced CD19 phosphorylation and enhance the interaction of pCD19 with the BCR.

Arp2/3 complex activity is important for BCR-induced B cell activation responses {#s2-8}
--------------------------------------------------------------------------------

We next sought to determine if the early BCR signaling defects observed in B cells treated with the Arp2/3 complex inhibitor translated into reduced B cell activation responses at later times. In [Figure 9](#fig9){ref-type="fig"}, we show that COS-7 APCs expressing the single chain anti-Ig$\kappa$ surrogate Ag induce primary B cells to undergo robust transcriptional responses, activation marker upregulation, cell size increase, and proliferation. We then assessed whether inhibiting Arp2/3 complex activity by treating the cells with CK-666 impacted these BCR-mediated responses that occur after 3--72 hr of Ag stimulation ([Figure 9A](#fig9){ref-type="fig"}).

![Arp2/3 complex activity is required for B cell activation responses.\
(**A**) Readouts used to assess B cell activation in response to anti-Ig$\kappa$-expressing APCs. Primary murine B cells were pre-treated with CK-689 or CK-666 for 1 hr and then added to the APCs. The CK-689 or CK-666 was present in the co-culture for the entire length of the experiment unless otherwise indicated. (**B**) Histograms showing GFP fluorescence in primary ex vivo Nur77^GFP^ B cells exposed to anti-Ig$\kappa$-expressing COS-7 APCs (filled curves) or parental COS-7 cells (unfilled curves) for 3 hr. The Ag-induced increase in GFP fluorescence was calculated as the geometric mean for B cells cultured with anti-Ig$\kappa$-expressing APCs (dotted line) minus the geometric mean for B cells cultured with parental COS-7 cells. See [Figure 9---figure supplement 1A](#fig9s1){ref-type="fig"} for gating strategy. The graph shows the Ag-induced increase in GFP fluorescence in CK-666-treated B cells as a percent of the response in CK-689-treated control cells (=100%). Each dot is an independent experiment and the red line is the median. (**C,D**) Histograms showing CD69 (**C**) or CD86 (**D**) upregulation in primary ex vivo C57BL/6J B cells exposed to anti-Ig$\kappa$-expressing APCs (filled curves) or parental COS-7 cells (unfilled curves) for 18 hr. The Ag-induced increases in CD69 or CD86 expression were calculated as in (**B**). See [Figure 9---figure supplement 2](#fig9s2){ref-type="fig"} for gating strategy and representative calculations. Graphs show the increase in expression in CK-666-treated B cells as a percent of the response in CK-689-treated controls (=100%). Each dot is an independent experiment. The median (red line) and interquartile ranges (box) are shown. (**E**) Induction of CD86 expression in response to APCs (calculated as above) or to PMA +ionomycin (geometric mean for stimulated B cells minus geometric mean for unstimulated B cells) in the same experiment. Responses by CK-666-treated B cells are expressed as a percent of those in the CK-689-treated control cells. Results from two experiments are shown along with the average (bar). (**F**) B cells were pre-treated with CK-689 or CK-666 for 1 hr before being added to anti-Ig$\kappa$-expressing APCs or parental COS-7 cells (−60 min time point). Alternatively, the drugs were added at the same time that the B cells (0 min) were added to the APCs or parental COS-7 cells, or at 5--60 min after initiating the co-culture. The Ag-induced increase in CD69 expression after 18 hr of co-culture was calculated as above and responses by CK-666-treated B cells are expressed as a percent of those in the CK-689-treated control cells. For each point, the average ± range is shown for two experiments. (**G**) B cells were pre-treated with CK-689 or CK-666 for 1 hr prior to being added to anti-Ig$\kappa$-expressing APCs. After 18 hr of co-culture, the percent of blast cells with increased forward and side scatter was determined by flow cytometry (see [Figure 9---figure supplement 2](#fig9s2){ref-type="fig"} for gating strategy). Each dot is an independent experiment. The median (red line) and interquartile ranges are shown. (**H**) CFSE-labeled B cells were pre-treated with CK-689 or CK-666 for 1 hr prior to being cultured with APCs, IL-4, and BAFF for 3 days (filled curves). The unfilled curves depict CFSE dilution at Day 1. Representative data from one experiment is shown on the left and the average number of divisions per cell is indicated. The graph in the center shows the percent of live cells that had proliferated by Day 3. The percent of dead B cells that stained with 7-AAD is shown (right). Where indicated, CK-666 was added 24 hr after initiating the B cell-APC co-culture instead of 1 hr prior. In the graphs, each dot is an independent experiment and the bars indicate medians. \*\*\*\*p\<0.0001; \*\*\*p\<0.001; \*\*p\<0.01; \*p\<0.05; ns, not significant. Two-tailed paired t-test.](elife-44574-fig9){#fig9}

To assess BCR-induced transcriptional responses, we used B cells from Nur77^GFP^ reporter mice in which GFP expression is under the control of the *Nur77* promoter ([@bib66]). *Nur77* is an immediate early gene whose transcription is induced in lymphocytes by TCR or BCR engagement. Primary Nur77^GFP^ B cells were incubated with COS-7 cells expressing the single chain anti-Ig$\kappa$ surrogate Ag, or with parental COS-7 cells (no surrogate Ag), in the presence of CK-689 or CK-666. GFP expression was measured by flow cytometry after 3 hr (see [Figure 9---figure supplement 1](#fig9s1){ref-type="fig"} for gating strategy). In the absence of surrogate Ag expression by the COS-7 cells, Nur77^GFP^ B cells did not adhere to the COS-7 cells and GFP expression was not increased relative to B cells that were cultured in the absence of COS-7 cells ([Figure 9---figure supplement 1B,C](#fig9s1){ref-type="fig"}). By contrast, culturing Nur77^GFP^ B cells with anti-Ig$\kappa$-expressing COS-7 cells resulted in increased GFP expression compared to B cells that were cultured with parental COS-7 cells. Importantly, in the presence of the Arp2/3 inhibitor CK-666, this APC-induced increase in GFP expression was reduced to \~30% of the levels observed in control Nur77^GFP^ B cells treated with CK-689 ([Figure 9B](#fig9){ref-type="fig"}).

In the presence of APC-bound Ags, inhibition of Arp2/3 complex activity also impaired the ability of primary B cells to increase their cell surface levels of CD69, the canonical marker of lymphocyte activation, and CD86, a co-stimulatory ligand critical for T cell activation ([Figure 9C,D](#fig9){ref-type="fig"}). Culturing primary B cells with anti-Ig$\kappa$-expressing COS-7 APCs for 18 hr resulted in increased expression of CD69 and CD86 on the B cells ([Figure 9C,D](#fig9){ref-type="fig"}), responses that were completely dependent on expression of the surrogate Ag on the APCs ([Figure 9---figure supplement 2](#fig9s2){ref-type="fig"}). In CK-666-treated B cells, BCR-induced upregulation of CD69 and CD86 was inhibited by 40--50%. This was not due to increased B cell death, as DAPI-positive dead cells were excluded from analysis ([Figure 9---figure supplement 2](#fig9s2){ref-type="fig"}). Importantly, CD86 upregulation in response to PMA plus ionomycin was not affected by CK-666 ([Figure 9E](#fig9){ref-type="fig"}). Similar results were obtained for CD69 (data not shown). This suggests that inhibiting the Arp2/3 complex impairs proximal BCR signaling that is important for upregulation of CD86, as opposed to downstream events that are induced by both PMA plus ionomycin and BCR engagement.

In this co-culture system, both the B cells and the APCs are exposed to CK-666 for the entire duration of the experiment. To ensure that the observed reduction in CD69 and CD86 expression was not due to effects of CK-666 on the APCs, we used Arp3 siRNA to deplete the Arp2/3 complex in B16F1 murine melanoma cells expressing the single chain anti-Ig$\kappa$ Ag ([Figure 9---figure supplement 3A,B](#fig9s3){ref-type="fig"}). When primary B cells were added to these APCs, we observed that control and Arp3-depleted B16F1 APCs induced the upregulation of CD69 and CD86 to the same extent ([Figure 9---figure supplement 3C,D](#fig9s3){ref-type="fig"}). Moreover, B cells treated with CK-666 exhibited similarly impaired CD69 and CD86 responses, regardless of whether Arp3 was depleted or not in the APCs ([Figure 9---figure supplement 3E,F](#fig9s3){ref-type="fig"}). This indicates that the impaired upregulation of CD69 and CD86 observed in CK-666 treated cells is B cell-intrinsic.

Because the CK-666 was present during the entire B cell-APC co-culture in these experiments, it was also important to determine whether the impaired responses to APC-bound Ags were due to alterations in the initial BCR spatial reorganization and signaling, or to later events. To test this, we delayed the addition of CK-666. Pre-treating B cells with CK-666 for 1 hr prior to adding them to the APCs resulted in substantial inhibition of CD69 upregulation ([Figure 9C](#fig9){ref-type="fig"}). However, if the CK-666 was added 5 min after initiating the B cell-APC co-culture, or at later time points, it had very little effect on the BCR-induced upregulation of CD69 ([Figure 9F](#fig9){ref-type="fig"}). Adding CK-666 to the B cells at same time that they were mixed with the APCs caused only partial inhibition of the CD69 response compared to pre-treating the B cells for 1 hr with the drug. Similar results were obtained for CD86 (data not shown). This likely reflects the fact that some time is required for the CK-666 concentration in the B cells to reach a level that substantially inhibits Arp2/3 complex activity. Hence APC-induced B cell activation is only impaired if Arp2/3 complex activity is inhibited during the initial stages of B cell-APC interaction. Moreover, if CK-666 was present during the initial B cell-APC interaction, and then washed out after 5--120 min, CD69 upregulation was able to recover to nearly 100% of control values, regardless of when the washout was performed ([Figure 9---figure supplement 4A](#fig9s4){ref-type="fig"}). Once the drug was removed, the cells recovered their ability to aggregate BCR microclusters and form a cSMAC ([Figure 9---figure supplement 4B--D](#fig9s4){ref-type="fig"}) and B cell activation could proceed normally, consistent with the effects of CK-666 on actin dynamics being rapidly reversible ([@bib97]). Together, these results argue that Arp2/3 complex-dependent processes that occur during the initial stages of B cell-APC interactions are required for B cell activation responses.

Inhibition of the Arp2/3 complex results in dramatic alterations of the actin cytoskeleton at the immune synapse ([Figure 3](#fig3){ref-type="fig"}). It is possible that this disrupted actin architecture blocks contractile forces generated by myosin IIA ([@bib27]). In T cells, contractile forces generated by myosin IIA are important for centralizing TCR microclusters into a cSMAC ([@bib4]; [@bib46]; [@bib47]; [@bib54]; [@bib68]; [@bib98]). To assess the contribution of myosin contractility in our system, we treated primary B cells with para-nitro-blebbistatin (pnBB) to inhibit myosin. When pnBB-treated cells were added to COS-7 APCs expressing membrane-bound anti-Ig$\kappa$ for 18 hr, they exhibited a slight, but not statistically significant reduction in CD69 and CD86 upregulation compared to DMSO-treated cells ([Figure 9---figure supplement 5A,B](#fig9s5){ref-type="fig"}). Moreover, pnBB-treated A20 D1.3 B cells that were added to COS-7 APCs expressing mHEL-HaloTag were able to form cSMACs to the same extent as DMSO-treated cells ([Figure 9---figure supplement 5A,B](#fig9s5){ref-type="fig"}). These results suggest that APC-induced activation marker expression and cSMAC formation are dependent on Arp2/3 complex activity, whereas myosin contractility has little or no involvement, at least under these experimental conditions.

As part of their activation program, B cells increase in size as they enter S phase, reflecting an increase in the secretory machinery required for antibody synthesis ([@bib22]; [@bib53]). Compared to resting lymphocytes, activated lymphoblasts exhibit an increase in both forward scatter (cell size) and side scatter (granularity) when analyzed by flow cytometry. Co-culturing primary B cells with anti-Ig$\kappa$-expressing COS-7 APCs for 18 hr resulted in 30--55% of the B cells becoming larger, more granular blast cells ([Figure 9G](#fig9){ref-type="fig"}; [Figure 9---figure supplement 2C,D](#fig9s2){ref-type="fig"}). However, in the presence of the Arp2/3 complex inhibitor CK-666, the percent of B cells that became blast cells was reduced to 5--16% ([Figure 9G](#fig9){ref-type="fig"}).

In the presence of co-stimulatory cytokines such as BAFF and IL-4, Ag-activated B cells proliferate extensively. CFSE dilution assays showed that \>90% of primary B cells that were co-cultured with anti-Ig$\kappa$-expressing COS-7 APCs plus these cytokines for 72 hr had divided ([Figure 9H](#fig9){ref-type="fig"}). Addition of CK-666 to the culture reduced the percent of B cells that had divided at least once to \~55% and the mean number of cell divisions was reduced from 2 to 0.7 ([Figure 9H](#fig9){ref-type="fig"}). This reduction in B cell proliferation was accompanied by increased cell death ([Figure 9H](#fig9){ref-type="fig"}), which is the alternative fate for B cells that are cultured in vitro in the absence of mitogenic stimuli. Note that when the Arp2/3 inhibitor CK-666 was added 24 hr after initiating the B cell-APC co-culture, B cell proliferation was not impaired ([Figure 9H](#fig9){ref-type="fig"}, middle panel). This indicates that CK-666 does not block cell division and suggests that the critical functions of the Arp2/3 complex in APC-dependent B cell activation occur during the first 24 hr. Collectively, these findings indicate that the Arp2/3 complex-dependent processes are important for B cells to enter S phase and proliferate.

Discussion {#s3}
==========

Using high spatiotemporal resolution imaging of actin in B cells interacting with APCs, we observed that B cells scan the surface of the APC using complex and dynamic actin-rich protrusions that constantly extend and retract across the APC surface. This dynamic probing is mediated by Arp2/3 complex activity, which also generates retrograde actin flow that facilitates the initial centripetal movement of BCR microclusters and is required for cSMAC formation. Importantly, these Arp2/3 complex-dependent processes amplify proximal and distal BCR signaling, transcriptional responses, and B cell proliferation in response to APC-bound Ag.

In contrast to the highly dynamic lamellipodia and filopodia that B cells extend asymmetrically over the APC surface, the actin-rich protrusions that B and T cells form when they spread on Ag-bearing lipid bilayers ([@bib28]; [@bib68]) or Ag-coated coverslips ([@bib13]; [@bib29]) are predominantly symmetrical, sheet-like lamellipodia. This difference in spreading and probing behavior may reflect the physical properties of the Ag-bearing substrate. In fibroblasts and epithelial cells, stiffer substrates favor Rac1- and Arp2/3 complex-dependent formation of lamellipodia, whereas softer substrates favor Cdc42- and formin-dependent formation of filopodia ([@bib19]; [@bib95]). The greater prevalence of filopodia when B cells spread on APCs, compared to artificial lipid bilayers, is consistent with the finding that the APC membrane is less stiff than the artificial lipid bilayers that have been used to mimic APCs ([@bib69]). Whether local variations in the stiffness of the APC membrane shape B cell probing behavior is not known. However, the membranes of FDCs and dendritic cells differ in their stiffness ([@bib82]) and this could impact the type of probing behavior that B cells use to scan the surface of these APCs.

The filopodia-like structures formed by control B cells interacting with APCs allowed the formation of BCR-Ag microclusters at sites distant from the cell body. Branched actin networks that were nucleated around these linear protrusions then encased the BCR-Ag microclusters and generated centripetal flow that was required for BCR-Ag microcluster centralization. When the Arp2/3 complex was inhibited, lamellipodial branched actin protrusions were not generated in response to either APC-bound Ag or anti-Ig-coated coverslips, and instead the formation of filopodia was greatly enhanced. This is consistent with the idea that the Arp2/3 complex and formins compete for a limited pool of actin monomers ([@bib83]). In B cells in which the Arp2/3 complex was inhibited, the filopodia that formed were able to extend over the surface of the APC and gather Ag into microclusters. However, these filopodia and their associated BCR-Ag microclusters, were not efficiently retracted toward the cell body.

We showed that Arp2/3 complex-dependent branched actin nucleation is essential for actin retrograde flow at the cell periphery and is required for BCR-Ag microcluster centralization and cSMAC formation. In T cells, both pushing forces generated by actin retrograde flow and contractile forces generated by actomyosin arcs have been shown to drive the centripetal movement of TCR microclusters to form a cSMAC ([@bib4]; [@bib46]; [@bib47]; [@bib54]; [@bib68]; [@bib98]). In B cells spreading on anti-Ig-coated coverslips, we observed that similar actomyosin arcs formed at the inner face of the peripheral ring of branched actin. Consistent with the idea that these linear actin arcs are generated by formins, these structures appeared to form in B cells in which the Arp2/3 complex was inhibited, as has been observed in T cells ([@bib68]). Myosin IIA is important for B cells to extract Ags from APC membranes ([@bib45]; [@bib69]) and has been implicated in BCR microcluster centralization ([@bib84]). However, inhibition of myosin IIA did not affect cSMAC formation or the upregulation of B activation markers in our system. Although this does not rule out a role for myosin in B cell immune synapse formation and APC-induced B cell activation, it highlights that the Arp2/3 complex has a more important role in these processes, at least in our experimental system.

TCR microcluster centralization and cSMAC formation in T cells has been proposed to involve three cytoskeleton-dependent mechanisms that act sequentially: actin retrograde flow, actomyosin contraction, and movement along microtubules that span the actin-poor central region of the immune synapse ([@bib55]). Dynein-dependent movement of BCR and TCR microclusters along juxtamembrane microtubules is required for cSMAC formation in both B and T cells ([@bib43]; [@bib79]). We have shown that the formation of branched actin at the periphery of the immune synapse is required for capturing the plus ends of microtubules and for moving the microtubule network toward the Ag-presenting surface ([@bib91]). In B cells spreading on anti-Ig-coated coverslips, microtubule plus end binding proteins contact the inner face of the dense peripheral actin ring, which is depleted of microtubules, much like the leading edge of a migrating cell. Hence, initial microcluster centralization mediated by Arp2/3 complex-dependent actin retrograde flow may be required for BCR microclusters to associate with microtubules and coalesce into a cSMAC at the center of the immune synapse. Thus, inhibiting Arp2/3 complex activity may block a critical initial step in BCR-Ag microcluster centralization and prevent the microtubule-based centralization that leads to cSMAC formation, the site where Ags are often internalized.

We showed that Arp2/3 complex activity amplifies BCR signaling in response to APC-bound Ags. The molecular mechanisms by which the actin cytoskeleton regulates Ag receptor signaling are still being explored. In T cells, actin retrograde flow is important for sustained TCR signaling in response to Ag-bearing artificial lipid bilayers ([@bib4]; [@bib56]). Because the TCR is a mechanosensitive receptor, actin retrograde flow could exert tension on the TCR that enhances its signaling ([@bib5]). The BCR is also highly sensitive to mechanical force, such that increasing the stiffness of Ag-presenting surfaces causes greater recruitment of Syk and other signaling components ([@bib89]; [@bib90]). Hence, Arp2/3 complex-dependent actin retrograde flow could increase the mechanical tension on Ag-bound BCRs and enhance their signaling. Consistent with this idea, we observed that peak BCR signaling occurred during the first 5 min of APC encounter, when BCR-Ag microclusters are undergoing the greatest centripetal movement.

BCR signaling is enhanced by the formation of large and stable microclusters, which is dependent on Ag mobility and the actin cytoskeleton ([@bib52]). In control B cells, microcluster size increased most rapidly between 2 and 6 min after the B cells were added to the APCs, which corresponds with the peak of proximal BCR signaling. Inhibition of the Arp2/3 complex decreased both microcluster merge events and BCR signaling, consistent with the idea that actin-dependent microcluster aggregation enhances BCR signaling. Microcluster growth may increase the frequency at which Ag-bound BCRs that have recruited Syk can trap BCRs that are not bound to Ag, and activate them via Syk-mediated phosphorylation. Alternatively, larger microclusters may more efficiently shield activated BCRs from negative regulators such as CD22 ([@bib33]).

Arp2/3 complex-dependent actin polymerization could also enhance BCR signaling by maintaining the integrity of the BCR-Ag microclusters and by acting as a platform for the assembly of signaling complexes. We observed that BCR-Ag microclusters were surrounded by actin cages. The idea that these cages maintain the integrity of BCR microclusters is supported by the finding that microclusters become more diffuse when B cells are treated with the actin-depolymerizing drug latrunculin A ([@bib87]). In T cells, signaling proteins such as PLCγ1 accumulate at actin foci that surround TCR microclusters ([@bib56]). Deletion of WASp or inhibition of the Arp2/3 complex has no effect on proximal TCR signaling or microcluster formation but results in impaired recruitment and activation of PLCγ1 ([@bib56]). Whether Arp2/3 complex-dependent actin structures surrounding BCR microclusters act as scaffolds that amplify and diversify BCR signaling remains to be determined.

Although Ag-induced actin reorganization enhances BCR signaling, the submembrane actin cytoskeleton limits the lateral mobility of the BCR in resting B cells and thereby prevents spontaneous BCR signaling. Indeed, disrupting the actin cytoskeleton with latrunculin A is sufficient to induce robust Ag-independent BCR signaling ([@bib86]). We found that inhibiting Arp2/3 complex activity in resting primary B cells resulted in increased basal levels of pERK and pAkt, and that this correlated with increased lateral mobility of both IgM-BCRs and IgD-BCRs within the plasma membrane. Hence, Arp2/3 complex-mediated actin polymerization is also important for maintaining the quiescent state of resting B cells and for preventing aberrant Ag-independent BCR signaling.

We also showed that Arp2/3 complex activity enhances functional interactions between the BCR and its co-receptor CD19. Ag binding promotes the tyrosine phosphorylation of CD19, allowing it to recruit key effectors of BCR signaling such as PI3K and Vav. CD19 associates with the Lyn tyrosine kinase, which can phosphorylate the CD79a/b signaling subunit of the BCR, and has also been reported to enhance recruitment of the Syk and Btk tyrosine kinases to the BCR ([@bib23]; [@bib31]; [@bib32]). Hence, the interaction of the BCR with CD19 facilitates processive signaling reactions that amplify BCR signaling. We found that inhibiting the Arp2/3 complex resulted in decreased CD19 phosphorylation, as well as reduced overlap between BCR-Ag clusters and pCD19 clusters, at 3 min after the initiating B cell-APC contact. By 5 min, the differences between CK-666-treated B cells and control cells were smaller. Hence, inhibiting the Arp2/3 complex reduces and delays initial Ag-induced BCR-CD19 interactions. Initial BCR-CD19 interactions are dependent on the immobilization of CD19 by the tetraspanin network ([@bib62]). We found that inhibiting Arp2/3 complex-dependent actin polymerization increased the lateral mobility of CD19 within the plasma membrane, suggesting that branched actin structures also restrain its mobility. This increased mobility of CD19 may decrease the initial rate at which productive BCR-CD19 collisions occur.

Although inhibiting the Arp2/3 complex significantly reduced proximal BCR signaling during the first 5 min of B cell-APC encounter, a key question was whether this would translate into decreased B cell activation. Indeed, CK-666 treatment reduced the ability of Ag-bearing APCs to stimulate a transcriptional response at 3 hr, activation marker upregulation at 18 hr, and B cell proliferation at 72 hr. Importantly, we found that adding CK-666 to B cells shortly after they had engaged APCs did not impair the upregulation of B cell activation markers. As well, we found that Arp2/3 complex activity was not required for the upregulation of activation markers in response to PMA plus ionomycin, stimuli that bypass the BCR but initiate many of the same downstream signaling reactions. Taken together, these findings support the idea that Arp2/3 complex-dependent effects on BCR-Ag microclusters that occur within the first few minutes of B cell-APC interactions amplify initial BCR signaling reactions that are translated into B cell responses that occur up to 3 days later.

Consistent with our findings that Arp2/3 complex activity regulates both tonic BCR signaling and APC-induced B cell activation, upstream activators of the Arp2/3 complex are important regulators of B cell activation. Murine B cells lacking WASp, an NPF that activates the Arp2/3 complex, exhibit reduced cell spreading, BCR-Ag microcluster formation, and BCR-induced tyrosine phosphorylation in response to Ag-bearing lipid bilayers ([@bib58]). The WASp-interacting protein WIP regulates the activity and subcellular distribution of WASp, and also stabilizes existing actin filaments. Murine B cells lacking WIP have defective CD19-mediated PI3K signaling and antibody responses ([@bib51]). WASp activation is regulated by the Cdc42 GTPase and B-cell-specific loss of Cdc42 results in aberrant actin organization, diminished BCR signaling, and a severe impairment in antibody production ([@bib14]).

In line with its central role in many aspects of B cell function, human mutations that impair the activation Arp2/3 complex result in disease. Mutations in WASp or WIP result in Wiskott-Aldrich syndrome, an X-linked immunodeficiency disorder ([@bib15]). Similarly, missense mutations in the *ARPC1B* gene have recently been described as causing a Wiskott-Aldrich syndrome-like disease ([@bib50]). Although Wiskott-Aldrich syndrome is associated with increased susceptibility to infections, many patients also develop autoimmunity and B-cell malignancies ([@bib15]). Our finding that the loss of Arp2/3 complex activity in B cells results in increased tonic BCR signaling but impaired APC-induced B cell activation may help explain this paradox.

Materials and methods {#s4}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type                    Designation                                       Source or reference                                              Identifiers                                                              Additional\
                                                                                                                                                                                                                              information
  ------------------------------- ------------------------------------------------- ---------------------------------------------------------------- ------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------
  Sequence-based reagent          ON-TARGETplus Non-Targeting Pool,                 Dharmacon                                                        \#D-001810-01-05                                                         

  Sequence-based reagent          SMARTpool ON-TARGETplus, Dharmacon,               Dharmacon                                                        \#L-046642-01-0005                                                       

  Other                           RPMI-1640 without phenol red                      Life Technologies                                                \#32404014                                                               

  Antibody                        Goat anti-mouse IgG                               Jackson ImmunoResearch                                           \#115-005-008                                                            Coverslip coating 2.5 µg/cm^2^

  Antibody                        Goat anti-mouse IgM                               Jackson ImmunoResearch                                           \#115-005-020                                                            Coverslip coating 2.5 µg/cm^2^

  Antibody                        Rabbit anti-pZap70(Y319)/pSyk(Y352)               Cell Signaling Technologies                                      \#2701                                                                   Immunofluorescence 1:200

  Antibody                        Rabbit anti-pCD79a(Y182)                          Cell Signaling Technologies                                      \#5173                                                                   Immunofluorescence 1:400, Western blot 1:1000

  Antibody                        Rabbit anti-CD79a                                 [@bib35]                                                                                                                                  Western blot 1:5000

  Antibody                        Rabbit anti-pCD19(Y531)                           Cell Signaling Technologies                                      \#3571                                                                   Immunofluorescence 1:200, Western blot 1:1000

  Antiboday                       Rabbit anti-CD19                                  Cell Signaling Technologies                                      \#3574                                                                   Western blot 1:1000

  Antibody                        Alexa Fluor 488 goat anti-rabbit IgG              Invitrogen                                                       \#A-11008                                                                Immunofluorescence 1:400

  Antibody                        Alexa Fluor 647 goat anti-rat IgG                 Invitrogen                                                       \#A-21247                                                                Immunofluorescence 1:400

  Antibody                        Goat anti-mouse Ig kappa                          Southern Biotech                                                 \#1050--01                                                               Stimulation 20 µg/ml

  Antibody                        Rabbit anti-ACTR3 (Arp3)                          Santa Cruz                                                       \#sc-15390                                                               Western blot 1:1000

  Antibody                        Rabbit anti-Arp2                                  Abcam                                                            \#ab128934                                                               Western blot 1:1000

  Antibody                        Mouse anti-β-actin                                Santa Cruz                                                       \#sc-47778                                                               Western blot 1:5000

  Antibody                        Rabbit anti-p34-Arc/ARPC2                         Millipore                                                        \#07--227                                                                Western blot 1:1000

  Antibody                        Rabbit anti-pERK                                  Cell Signaling Technologies                                      \#9101                                                                   Western blot 1:1000

  Antibody                        Rabbit anti-ERK                                   Cell Signaling Technologies                                      \#9102                                                                   Western blot 1:1000

  Antibody                        Rabbit anti-pAkt                                  Cell Signaling Technologies                                      \#9271                                                                   Western blot 1:1000

  Antibody                        Rabbit anti-Akt                                   Cell Signaling Technologies                                      \#9272                                                                   Western blot 1:1000

  Antibody                        Goat anti-rabbit IgG(H + L)-HRP conjugate         Bio-Rad                                                          \#170--6515                                                              Western blot 1:3000

  Antibody                        Goat anti-mouse IgM Fab fragment-Cy3-conjugated   Jackson ImmunoResearch                                           \#115-167-020                                                            Single particle tracking 1 ng/ml

  Antibody                        Rat anti-mouse IgD Fab fragment-Cy3-conjugated    ATCC                                                             \#HB-250 (11--26 c)                                                      Fab made by AbLab; SPT 100 ng/ml

  Antibody                        Rat anti-mouse CD19 Fab fragment-Cy3-conjugated   ATCC                                                             \#HB-305 (1D3)                                                           Fab made by AbLab; SPT 10 ng/ml

  Antibody                        Rabbit anti-MHC II monoclonal antibody (M5/114)   Millipore                                                        \#MABF33                                                                 Coverslip coating 0.25 µg/cm^2^

  Antibody                        2.4G2 monoclonal antibody                         ATCC                                                             \#HB-197                                                                 0.25 µg/ml

  Antibody                        Anti-CD69-FITC                                    eBioscience                                                      \#11-0691-82                                                             Flow cytometry 1:200

  Antibody                        Anti-CD86-APC                                     eBioscience                                                      \#17-0862-82                                                             Flow cytometry 1:200

  Biological sample (bovine)      Fibronectin                                       Sigma-Aldrich                                                    \#F4759                                                                  Coverslip coating 5 µg/ml

  Cell line (C. aethiops)         COS-7                                             American Type Culture Collection                                 \#CRL-1651; RRID:[CVCL_0224](https://scicrunch.org/resolver/CVCL_0224)   

  Cell line (M. musculus)         A20                                               American Type Culture Collection                                 \#TIB-208; RRID:[CVCL_1940](https://scicrunch.org/resolver/CVCL_1940)    

  Cell line (M. musculus)         A20 D1.3                                          [@bib8]                                                                                                                                   F Batista (Ragon Institute, Cambridge, MA)

  Cell line (M. musculus)         B16F1                                             American Type Culture Collection                                 \#CRL-6323; RRID:[CVCL_0158](https://scicrunch.org/resolver/CVCL_0158)   

  Chemical compound, drug         CK-666                                            Calbiochem                                                       \#CAS 442633-00-3                                                        100 µM

  Chemical compound, drug         CK-689                                            Calbiochem                                                       \#CAS 170930-46-8                                                        100 µM

  Chemical compound, drug         (S)-nitro-blebbistatin (pnBB)                     Cayman Chemicals                                                 \#CAS 856925-71-8                                                        50 µM

  Chemical compound, drug         HaloTag Janelia Fluor 549 ligand                  Promega                                                          \#GA1110                                                                 Cell labeling 1:2000

  Chemical compound, drug         HaloTag tetramethylrhodamine ligand               Promega                                                          \#G8251                                                                  Cell labeling 1:2000

  Chemical compound, drug         Rhodamine phalloidin                              Thermo Fisher                                                    \#R415                                                                   Immunofluorescence 1:1000

  Chemical compound, drug         Alexa Fluor 568-conjugated phalloidin             Thermo Fisher                                                    \#A12380                                                                 Immunofluorescence 1:1000

  Chemical compound, drug         Alexa Fluor 532-conjugated-phalloidin             Thermo Fisher                                                    \#A22282                                                                 Immunofluorescence 1:1000

  Chemical compound, drug         ProLong Diamond anti-fade reagent                 Thermo Fisher                                                    \#P36965                                                                 

  Chemical compound, drug         ECL detection reagent                             GE Life Sciences                                                 \#RPN2106                                                                

  Chemical compound, drug         CFSE                                              Invitrogen                                                       \#C1157                                                                  Flow cytometry 2 µM

  Chemical compound, drug         7-AAD                                             Thermo Fisher                                                    \#A1310                                                                  Flow cytometry 1:1000

  Commercial assay or kit         B cell isolation kit                              Stemcell Technologies                                            \#19854A                                                                 

  Commercial assay or kit         AMAXA nucleofector kit V                          Lonza                                                            \#VCA-1003                                                               

  Commercial assay or kit         Ingenio electroporation solution                  Mirus                                                            \#MIR 50117                                                              

  Commercial assay or kit         Lipofectamine 3000                                Thermo-Fisher                                                    \#L3000008                                                               

  Commercial assay or kit         Fab preparation kit                               Pierce                                                           \#44985                                                                  

  Genetic reagent (M. musculus)   C57BL/6J                                          Jackson Laboratories                                             Stock \#000664; MGI:3028467                                              

  Genetic reagent (M. musculus)   C57BL/6-Tg(IghelMD4)4Ccg/J                        Jackson Laboratories                                             Stock \#002595; MGI:2384162                                              [@bib37]

  Genetic reagent (M. musculus)   C57BL/6-Tg(Nr4a1-EGFP/cre)820Khog                 [@bib66]                                                         MGI:5007644                                                              PMID:[21606508](https://www.ncbi.nlm.nih.gov/pubmed/21606508); K Hogquist (University of Minnesota)

  Peptide, recombinant protein    BAFF                                              R&D Systems                                                      \#8876-BF-010                                                            5 ng/ml

  Peptide, recombinant protein    IL-4                                              R&D Systems                                                      \#404 ML-010                                                             5 ng/ml

  Recombinant DNA reagent         F-tractin-GFP                                     [@bib49]                                                                                                                                  

  Recombinant DNA reagent         Myosin IIA-GFP                                    Addgene                                                          \#38297                                                                  

  Recombinant DNA reagent         mHEL-GFP                                          [@bib6]                                                                                                                                   F Batista (Ragon Institute, Cambridge, MA)

  Recombinant DNA reagent         mHEL-HaloTag                                      PMID: [29388105](https://www.ncbi.nlm.nih.gov/pubmed/29388105)                                                                            M Gold (University of British Columbia)

  Recombinant DNA reagent         Single-chain anti-mouse Ig kappa antibody         [@bib3]                                                                                                                                   D Nemazee (Scripps Reseach Institute)

  Recombinant DNA reagent         β-Actin-GFP                                                                                                                                                                                 R Nabi (University of British Columbia)

  Software, algorithm             ISIM deconvolution                                PMID: [26210400](https://www.ncbi.nlm.nih.gov/pubmed/26210400)                                                                            

  Software, algorithm             Softworx                                          Applided Precision Ltd.; GE Healthcare Life Sciences                                                                                      

  Software, algorithm             FIJI                                              [@bib78]                                                                                                                                  <https://imagej.net/Fiji>

  Software, algorithm             MATLAB                                            MathWorks                                                        R2015b                                                                   

  Software, algorithm             MetaMorph                                         Molecular Devices                                                                                                                         

  Software, algorithm             ICY                                               [@bib21]                                                                                                                                  <http://icy.bioimageanalysis.org>

  Software, algorithm             FlowJo                                            Tree Star                                                        v10.5.3                                                                  

  Software, algorithm             Robust Regression and Outlier Removal (ROUT)      Graphad                                                          v7                                                                       [@bib67]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

B cells {#s4-1}
-------

Spleens were obtained from 8- to 12 week old C57BL/6J (Jackson Laboratories, \#000664), Nur77^GFP^([@bib66]), or MD4 ([@bib37]) (Jackson Laboratories, \#002595) mice of either sex following protocols approved by the University of British Columbia Animal Care Committee. B cells were isolated using a negative selection B cell isolation kit (Stemcell Technologies, \#19854A). The A20 murine IgG^+^ B-cell line (confirmed to be IgG^+^ by flow cytometry and responsive to anti-mouse IgG antibodies) was obtained from ATCC (\#TIB-208). A20 D1.3 B cells expressing a transgenic HEL-specific BCR (confirmed to express both mouse IgG and IgM (the transfected D1.3 BCR) and to be responsive to HEL) were a gift from F. Batista (Ragon Institute, Cambridge, MA) ([@bib8]). All cell lines were confirmed to be free of mycoplasma contamination. A20 B cells were cultured in RMPI-1640 supplemented with 5% fetal calf serum (FCS), 2 mM glutamine, 1 mM pyruvate, 50 µM 2-mercaptoethanol, 50 U/ml penicillin, and 50 µg/ml streptomycin (complete medium). A20 and A20 D1.3 B cells (3 × 10^6^ cells) were transiently transfected using the AMAXA nucleofector kit V (Lonza, \#VCA-1003) or the Ingenio electroporation kit (Mirus, \#MIR 50117) with 1.5 µg of either control siRNA (ON-TARGETplus Non-Targeting Pool, Dharmacon, \#D-001810-01-05) or Actr3 siRNA (SMARTpool ON-TARGETplus, Dharmacon, \#L-046642-01-0005), or with 2 µg of plasmid DNA encoding either F-tractin-GFP ([@bib49]) or myosin IIA-GFP (Addgene, \#38297) ([@bib48]). Transfected cells were cultured for 24 hr before use. Where indicated, B cells (7.5 × 10^5^ cells/ml) were pre-treated with 100 µM of the Arp2/3 complex inhibitor CK-666 (Calbiochem, \#CAS 442633-00-3) or the inactive analog CK-689 (Calbiochem, \#CAS 170930-46-8) ([@bib44]) for 1 hr at 37°C or with 50 μM of the myosin IIA inhibitor pnBB (Cayman Chemicals, \#CAS 856925-71-8) or DMSO for 30 min at 37°C.

APCs {#s4-2}
----

APCs were generated as described previously ([@bib29]; [@bib91]; [@bib92]). Briefly, COS-7 cells (ATCC, \#CRL-1651) or B16F1 cells (ATCC, \#CRL-6323) were transiently transfected using Lipofectamine 3000 (Thermo Fisher, \#L3000008) with plasmid DNA encoding either mHEL-GFP, mHEL-HaloTag, or a single-chain anti-Ig$\kappa$ antibody. mHEL-GFP is a transmembrane protein consisting of the complete HEL and GFP proteins in the extracellular domain, fused to the transmembrane region and cytosolic domain of the H-2K^b^ protein ([@bib6]). mHEL-HaloTag consists of the complete HEL protein fused to the transmembrane region and cytosolic domain of H-2K^b^, with the the HaloTag protein fused to the C-terminus (see [Figure 1](#fig1){ref-type="fig"}) ([@bib92]). The single-chain anti-Ig$\kappa$ antibody is a transmembrane protein consisting of the single-chain Fv with the variable regions from the 187.1 rat anti-Ig$\kappa$ monocolonal antibody, fused to the hinge and membrane-proximal domains of rat IgG1 and the transmembrane and cytoplasmic domains of the H-2K^b^ protein ([@bib3]). Where indicated, B16F1 cells were cotransfected with 1.5 μg of either control siRNA (ON-TARGETplus Non-Targeting Pool, Dharmacon, \#D-001810-01-05) or Actr3 siRNA (SMARTpool ON-TARGETplus, Dharmacon, \#L-046642-01-0005). The transfected cells were cultured in DMEM supplemented with 5% FCS, 2 mM glutamine, 1 mM pyruvate, 50 U/ml penicillin, and 50 µg/ml streptomycin for 24 hr before being used for experiments.

Fluorescence recovery after photobleaching {#s4-3}
------------------------------------------

COS-7 cells that had been transfected with actin-GFP (1.5 × 10^5^ cells) were plated onto fibronectin-coated coverslips and cultured overnight. Fluorescence recovery after photobleaching was performed as described previously ([@bib29]) using an Olympus FV1000 confocal microscope with a 100X NA 1.40 oil objective. Briefly, within a selected region of interest (ROI), the pre-bleached fluorescence intensity was measured, followed by photobleaching using the 405 nm laser (100% intensity for 3 s). Fluorescence recovery within the same ROI was then recorded for 40 s. FluoView v4.0 (Olympus) software was used to quantify the fluorescence within the ROI, which was then normalized to the pre-bleach fluorescence intensity.

BCR microcluster dynamics {#s4-4}
-------------------------

Live cell imaging of BCR-Ag microcluster dynamics was performed as described previously ([@bib92]). mHEL-GFP-expressing COS-7 cells were plated onto fibronectin-coated coverslips and cultured overnight. The coverslip was then washed with modified HEPES-buffered saline (mHBS; 25 mM HEPES, pH 7.2, 125 mM NaCl, 5 mM KCl, 1 mM CaCl~2~, 1 mM Na~2~HPO~4~, 0.5 mM MgSO~4~, 1 mg/ml glucose, 2 mM glutamine, 1 mM pyruvate, 50 µM 2-mercaptoethanol) supplemented with 2% FCS (imaging medium) and mounted onto the microscope in a 37°C imaging chamber. A20 D1.3 B cells were pre-treated with CK-689 or CK-666 for 1 hr in imaging medium. The B cells (5 × 10^5^ in 0.1 ml) were then added to the COS-7 APCs and imaging was started immediately. Imaging was performed using a spinning disk confocal microscope system (Intelligent Imaging Innovations) consisting of a Zeiss Axiovert 200M microscope with a 100X NA 1.45 oil Pan-Fluor objective and a QuantEM 512SC Photometrics camera. Z-stacks with 0.2-µm optical z-slices through the B cell-APC contact site were acquired at 12 s intervals. Alternatively, F-tractin-GFP-expressing A20 D1.3 B cells were pre-treated with CK-689 or CK-666, added to mHEL-HaloTag-expressing COS-7 cell APCs that had been labeled with the Janelia Fluor 549 dye ([@bib38]), and imaged using 3D-ISIM ([@bib99]). Z-stacks through the B cell-APC contact site were acquired every 6.6 s and the images were deconvolved as described ([@bib99]). Briefly, the images were subjected to 10 iterations of Richardson-Lucy deconvolution with a Gaussian point spread function having a full width half maximum (0.22 µm lateral and 0.5 µm axial) that was derived from measurements of 100 nm yellow/green beads. Within a single experiment, all images were acquired using identical settings. FIJI software ([@bib78]) was used to quantify cell area and generate kymographs. Custom FIJI macros were used to quantify the fluorescence intensity of Ag in microclusters and microcluster size (<https://github.com/madscience12/FIJImacros/blob/master/APC_analyzer_MBM.ijm>) as well as the distance between each microcluster and the center of the immune synapse (<https://github.com/madscience12/FIJImacros/blob/master/distance_macro_MBM.ijm>; [@bib11]).

Actin organization and dynamics in B cells spreading on anti-Ig-coated coverslips {#s4-5}
---------------------------------------------------------------------------------

Glass coverslips were coated with 2.5 µg/cm^2^ goat anti-mouse IgG (for A20 B cells; Jackson ImmunoResearch, \#115-005-008) or goat anti-mouse IgM (for primary B cells; Jackson ImmunoResearch, \#115-005-020) as described ([@bib57]). B cells were pre-treated for 1 hr with CK-666 or CK-689 before adding 7.5 × 10^4^ cells in 0.1 ml imaging medium to the coverslips. Cells were fixed and permeabilized as described below for immunostaining. F-actin was visualized using rhodamine- or Alexa Fluor 568-conjugated phalloidin (Thermo Fisher, \#R415, \#A12380, respectively; 1:1000). For live cell imaging at 37°C, F-tractin-GFP-expressing A20 B cells were imaged using either a Zeiss LSM 880 Airyscan microscope in super-resolution mode with a 63X 1.4 NA objective or a TIRF-SIM microscope (DeltaVision OMX-SR, GE Healthcare Life Sciences) equipped with a 60X 1.42 NA objective (Olympus). For Airyscan images, raw data were processed using automatically determined parameters. For TIRF-SIM images, raw data were reconstructed using Softworx (Applied Precision Ltd.; GE Healthcare Life Sciences) and with a value of 0.01 for the Wiener filter constant. Alternatively, the cells were fixed at the indicated times with 4% paraformaldehyde (PFA), permeabilized, and stained for F-actin as described below. FIJI software ([@bib78]) was used to quantify cell area and generate kymographs.

STED microscopy {#s4-6}
---------------

STED microscopy was performed as described previously ([@bib92]). Briefly, 5 × 10^4^ A20 B cells in 0.1 ml imaging medium were allowed to spread on anti-IgG-coated coverslips before being fixed and stained with Alexa Fluor 532-conjugated-phalloidin (Thermo Fisher, \#A22282). STED images were acquired using a Leica TCS SP8 laser scanning STED system equipped with a 592 nm depletion laser, a CX PL APO 100X NA 1.40 oil objective, and a Leica HyD high sensitivity detector. Image deconvolution was performed using Huygens software (Scientific Volume Imaging, Hilversum, Netherlands).

Analysis of APC-induced BCR signaling by immunostaining {#s4-7}
-------------------------------------------------------

Primary murine B cells (10^5^ in 0.1 ml imaging medium) from C57BL/6J or MD4 mice that had been pre-treated with CK-689 or CK-666 were added to COS-7 APCs expressing either the single-chain anti-Ig$\kappa$ surrogate Ag or mHEL-HaloTag that was labeled with HaloTag tetramethylrhodamine ligand (Promega, \#G8251). After the indicated times at 37°C, the cells were fixed with 4% PFA for 10 min at room temperature. The cells were then permeabilized with 0.1% Triton X-100 in PBS for 3 min and blocked with 2% BSA in PBS for 30 min, both at room temperature. Primary antibodies that were diluted in blocking buffer (2% BSA in PBS) were added for 1 hr at room temperature, or overnight at 4°C for anti-pCD79. The primary antibodies, all from Cell Signaling Technologies, were: pZap70(Y319)/pSyk(Y352) (\#2701; 1:200), pCD79a(Y182) (\#5173; 1:400), and pCD19(Y531) (\#3571; 1:200). The coverslips were then incubated for 30 min at room temperature with a mixture of Alexa Fluor 488 goat anti-rabbit IgG (Invitrogen, \#A-11008; 1:400) secondary antibody, fluorophore-conjugated phalloidin to visualize F-actin, and Alexa Fluor 647 goat anti-rat IgG (Invitrogen, \#A-21247; 1:400) to detect the rat IgG1 portion of the surrogate Ag and thereby visualize Ag clusters. Coverslips were mounted onto slides using ProLong Diamond anti-fade reagent (Thermo Fisher, \#P36965).

Quantification of cluster-associated fluorescence and overlap {#s4-8}
-------------------------------------------------------------

The total fluorescence intensity of clustered Ag or clustered signaling molecules at the B cell-APC interface was quantified as follows using custom MATLAB code (<https://bitbucket.org/jscurll/bolger-munro_image_analysis_scripts/src/master/mask_fluorescence_img_LoG.m>; [@bib80]). Each image was filtered (i.e. convolved) with a 3 × 3 averaging filter to smooth noise. Then, the standard deviation of the background pixel intensities in the filtered image was estimated to be $\sigma = {{1.4826 \times {MAD}}{({F_{3 \times 3}{(I)}})}}$, where ${MAD}{({F_{3 \times 3}{(I)}})}$ is the median absolute deviation of the pixel intensities in the filtered image, $F_{3 \times 3}{(I)}$. A binary mask (Mask 1) was then defined by thresholding the pixel intensities in the filtered image at $N\sigma$ above the median intensity, where $N$=2 for pCD79, 2 for pSyk, and 3 for pCD19 experiments.

Next, the original, unfiltered image $I$ was filtered with Laplacian of Gaussian (LoG) filters of different widths $h$. Each LoG filter highlights fluorescent spots and edges of fluorescent features at a specific scale determined by $h$. Regions of approximately uniform pixel intensities become approximately zero after filtering with a LoG filter of width $h$ that is substantially smaller than the size of the uniform-intensity region. For each LoG-filtered image, ${LoG}_{h}{(I)}$, the standard deviation $\sigma_{h}$ of the background pixel values was again estimated as described above, that is $\sigma_{h} = {{1.4826 \times {MAD}}{({{LoG}_{h}{(I)}})}}$. A second binary mask (Mask 2) was then defined by identifying pixels that exceeded a threshold $N\sigma_{h}$ in ${LoG}_{h}{(I)}$ at any scale, where $N$=3 for pCD79, 5 for pSyk, or 4 for pCD19 experiments. Additionally, any pixel that passed this threshold was removed from the mask if its greatest negative response to the different LoG filters was greater than its maximum positive response. This last step helps to sharpen the edges of fluorescent features that could have been excessively blurred by filters of large width. A final binary mask was defined by taking the intersection of Mask 1 and Mask 2. Hence, pixels were retained in the final mask if and only if they were present in both Mask 1 and Mask 2.

To quantify fluorescence in an image, background fluorescence was estimated by calculating the median intensity of the pixels outside of the mask, and this was subsequently subtracted from the whole image. Next, the intensities of pixels outside of the mask were set to 0 to leave only those pixels that were present in the mask. Finally, these pixel intensities were summed to obtain the total fluorescence intensity in the image. For each B cell, the total fluorescence intensity derived in this manner for a given signaling molecule was normalized to the total fluorescence intensity of clustered Ag on the same B cell. To quantify overlap we used custom MATLAB code (<https://bitbucket.org/jscurll/bolger-munro_image_analysis_scripts/src/master/quantify_fluorescence_overlap.m>; [@bib80]) to calculate Manders' coefficients ([@bib61]) after processing the images as described above to subtract background fluorescence and extract fluorescent features defined by the mask.

Analysis of BCR signaling by immunoblotting {#s4-9}
-------------------------------------------

After being pre-treated for 1 hr with CK-666 or CK-689, 4 × 10^6^ primary B cells in 0.1 ml imaging medium were added to anti-Ig$\kappa$-expressing COS-7 cells. Alternatively, 4 × 10^6^ primary B cells in 0.1 ml of imaging medium were stimulated with 20 µg/ml soluble goat anti-mouse Ig$\kappa$ antibodies (Southern Biotech, \#1050--01). Cells were lysed in RIPA buffer (30 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Igepal (Sigma-Aldrich), 0.5% sodium deoxycholate, 0.1% SDS, 2 mM EDTA, 1 mM PMSF, 10 µg/ml leupeptin, 1 µg/ml aprotinin, 25 mM β-glycerophosphate, 1 µg/ml pepstatin A, 10 µg/ml soybean trypsin inhibitor, 1 mM Na~3~MoO~4~, 1 mM Na~3~VO~4~) and analyzed by immunoblotting. Filters were incubated overnight at 4°C with antibodies against Arp3 (Santa Cruz, \#sc-15390; 1:1000), Arp2 (abcam, \#ab128934; 1:1000), p34 (Millipore, \#07--227; 1:1000), actin (Santa Cruz, \#sc-47778; 1:5000), or CD79a ([@bib35]; 1:5000), or with the following antibodies from Cell Signaling Technologies: pCD79a (\#5173; 1:1000); pCD19 (\#3571; 1:1000); CD19 (\#3574; 1:1000); pERK (\#9101; 1:1000), ERK (\#9102; 1:1000), pAkt (\#9271; 1:1000), or Akt (\#9272; 1:1000). Immunoreactive bands were visualized using horseradish peroxidase-conjugated goat anti-rabbit IgG (Bio-Rad \#170--6515; 1:3000), followed by ECL detection (GE Life Sciences). Blots were quantified and imaged using a Li-Cor C-DiGit imaging system. [Figure 9---figure supplement 6](#fig9s6){ref-type="fig"} shows complete images of blots from which sections are shown in [Figures 6](#fig6){ref-type="fig"}, [Figure 7](#fig7){ref-type="fig"}, and [Figure 8](#fig8){ref-type="fig"}.

Single-particle tracking (SPT) {#s4-10}
------------------------------

SPT using directly-conjugated Fab fragments of antibodies was performed as described previously ([@bib2]). Primary B cells from C57BL/6J mice were resuspended to 10^7^ cell/ml in RPMI-1640 without phenol red (Life Technologies \#32404014) plus 5 mM HEPES. CK-666 or CK-689 was added to a final concentration of 100 µM and the cells were incubated for 1 hr at 37°C. The cells were then placed on ice and labeled for 5 min with 1 ng/ml Cy3-conjugated anti-mouse IgM Fab fragments (Jackson ImmunoResearch, \#115-167-020), 100 ng/ml Cy3-conjugated Fab fragments from the 11--26c rat anti-mouse IgD monoclonal antibody (ATCC, \#HB-250), or 10 ng/ml Cy3-conjugated Fab fragments of the 1D3 rat anti-mouse CD19 monoclonal antibody (ATCC, \#HB-305). Fab fragments of the 11--26c antibody and 1D3 antibody were prepared by AbLab (Vancouver, Canada) using a Fab preparation kit (Pierce, \#44985). The labeled B cells were then attached to coverslips that had been coated with 0.25 µg/cm^2^ of the non-stimulatory M5/114 anti-MHC II monoclonal antibody (Millipore, \#MABF33). SPT was carried out at 37°C using an Olympus total internal reflection fluorescence microscopy (TIRFM) system consisting of an inverted microscope (Olympus IX81) equipped with a 150X NA 1.45 TIRFM objective (Olympus), motorized filter wheel (Olympus), high-performance electorn multiplier (EM)-charge-coupled device (CCD) camera (Photometrics Evolve), and real-time data acquisition software (Metamorph). The 561 nm solid-state diode laser was used to excite Cy3-labeled samples. The TIRF plane was adjusted to yield a penetration depth of 85--90 nm from the coverslip and the cells were imaged for 10 s at 33 Hz.

Single particles were detected and tracked using Icy bioimaging analysis software ([@bib21]) with the UnDecimated Wavelet Transform Detector plug-in and the Multiple Hypothesis Spot-Tracking plug-in ([@bib16]; [@bib17]). Diffusion coefficients and confinement diameters were determined as described previously ([@bib2]). The diffusion model assumes that displacements arise from a two-dimensional Brownian diffusion process. Diffusion coefficients were calculated for individual tracks using a maximum likelihood estimation approach that accounts for noise due to positional errors in acquisition as well as blurring during acquisition ([@bib9]).

APC-induced expression of the Nur77-GFP reporter gene, CD69, and CD86 {#s4-11}
---------------------------------------------------------------------

COS-7 APCs expressing the anti-Ig$\kappa$ surrogate Ag (2 × 10^5^ cells per well) were cultured overnight in 12-well plates. Primary B cells from C57BL/6J mice or Nur77^GFP^ mice were incubated in complete medium with 100 µM CK-666 or CK-689 for 1 hr and then 10^6^ B cells were added to each well containing APCs. After co-culturing the cells for 18 hr, the B cells and APCs were removed from the wells by pipetting. GFP levels were quantified by flow cytometry. To quantify cell surface expression of CD69 or CD86, the cells were resuspended in ice-cold FACS buffer (PBS with 2% FCS), Fc receptors were blocked by adding 25 µg/ml of the 2.4G2 monoclonal antibody (ATCC, \#HB-197) for 5 min, and then the cells were stained for 30 min at 4°C with anti-CD69-FITC (eBioscience, \#11-0691-82 1:200), anti-CD86-APC (eBioscience, \#17-0862-82; 1:200), and DAPI (1:10,000) for 30 min. Fluorescence was quantified using an LSR II cytometer (Becton Dickinson) and the data were analyzed using FlowJo software (Treestar). Forward and side scatter, together with DAPI staining, were used to gate on single live (GFP-positive or DAPI-negative) B cells. The Ag-induced increase in fluorescence was calculated as the geometric mean for B cells cultured with anti-Ig$\kappa$-expressing APCs, minus the geometric mean for B cells cultured with parental COS-7 cells that do not express the surrogate Ag. The gating strategies and sample calculations are shown in [Figure 9---figure supplement 1](#fig9s1){ref-type="fig"} (GFP expression) and [Figure 9---figure supplement 2](#fig9s2){ref-type="fig"} (CD69, CD86).

CFSE proliferation and cell death assays {#s4-12}
----------------------------------------

COS-7 APCs expressing the anti-Ig$\kappa$ surrogate Ag (2 × 10^5^ cells per well) were cultured overnight in 12-well plates. Primary B cells from C57BL/6J mice were resuspended in complete medium and labeled with 2 µM CFSE (Invitrogen, \#C1157) for 8 min prior to being treated with CK-666 or CK-689 for 1 hr. The B cells were then added to the APCs and cultured in complete medium with 5 ng/ml BAFF (R&D Systems, \#8876-BF-010) and 5 ng/ml IL-4 (R&D Systems, \#404 ML-010). After 24--72 hr the cells were resuspended by pipetting, stained with 7-AAD (Thermo Fisher, \#A1310; 1:1000) to identify dead cells, and analyzed by flow cytometry using an LSR II flow cytometer. Forward and side scatter were used to gate on single B cells. CFSE fluorescence in live (7-AAD-negative) B cells was then quantified. FlowJo software was used to analyze the data.

Statistical analysis {#s4-13}
--------------------

Two-tailed paired t-tests were used to compare mean values for matched sets of samples. The Mann-Whitney U test was used to compare ranks in samples with many cells and high variability (e.g. dot plots for immunofluorescence signaling data). For signaling experiments, outliers were identified using Robust Regression and Outlier Removal (ROUT) in GraphPad Prism with Q set to 1% ([@bib67]). Kolmogorov-Smirnov tests were used to compare SPT cumulative frequency distributions and FRAP curves.
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Thank you for submitting your article \"Arp2/3 complex-driven spatial patterning of the BCR enhances immune synapse formation, BCR signaling and cell activation\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Arup Chakraborty as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Pavel Tolar (Reviewer \#1); Bebhinn Treanor (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This is a well done study that extends previous works on the organization of the B cell immune synapse and on the role of actin polymerization in BCR clustering, transport and signaling. The main conclusion is that actin polymerization specifically by the ARP2/3 complex drives movement and fusion of BCR/Ag clusters in B cells interacting with membrane antigen and that this boosts proximal BCR signaling as well as late events, such as B cell activation. These results are compatible with the previous idea that dynamic B cell lamellipodia are involved in grabbing antigen and that actin-based membrane shape, mechanics and flow promote BCR clustering and signaling.

The experimental system uses COS-7 cells expressing B cell antigen, which is good as this system mimics B cell-APC interactions better than artificial substrates. The COS-7 cells are paired with the established A20 B cell model, or in the signaling experiments with naive mouse B cells. The imaging and tools for visualisation of the immune synapse are cutting edge.

Using the CK666 inhibitor and siRNA, the authors report that actin polymerization through the ARP2/3 complex did not affect spreading of the B cells or the amount of the antigen gathered, but affected the movement and fusion of the antigen clusters. This is also illustrated by videos of the antigen flowing with the actin. SIM imaging of the B cells on glass substrates shows this clearly, as here the dramatic actin flow clearly depends on ARP2/3, similarly as it does in T cells.

The ARP2/3-inhibited cells show reduced proximal BCR signaling, particularly the early tyrosine phosphorylation of the BCR and of CD19, suggesting that the actin mediated movement and clustering is important in amplifying antigen-mediated B cell activation. Remarkably, the authors also see importance of this early ARP2/3 activity on late responses, such as expression of activation markers and proliferation, which are reduced in their intensity. Controls show that indeed this is through activity of ARP2/3 during the early contact of the B cells with the APCs. Inhibiting of ARP2/3 also leads to enhanced \"tonic\" signaling, similarly as inhibition of all actin polymerisation, suggesting that the ARP2/3-generated F-actin pool is the relevant structure regulating this aspect of BCR signaling.

Essential revisions:

The major concern with the otherwise excellent study is that the authors may overreach in some interpretations and there is some concern that the CK666 displays effects that go beyond the Arp3 siRNA, raising issues about interpretations based on CK666 using in this way (1 hr pretreat at 100 µM).

1\) Video 1 (Figure 1B) shows the process of BCR-Ag clustering and SMAC formation over time. Clusters appear (t=0-1min), presumably upon B-cell contact, clusters move \~1µm centripetally where they coalesce into larger assemblies t=2-3 min), a few straggler clusters flow into the central array (t=3-5 min) and a SMAC assembly forms by \~10 min) although the forces acting on clusters and driving coalescence into a single SMAC structure are not obvious. The example illustrated in this video is unique. BCR-Ag formation and clustering in other cells shown in other videos do not exhibit all of these properties. Specifically, centripetal movement of BCR-Ag clusters is not commonly observed.

2\) To assess BCR-Ag clustering and SMAC formation together with B-cell F-actin structures, the authors use F-tractin-GFP to visualize dynamic B-cell actin structures and BCR-Ag clustering after B-cells contact an APC (Video 2). BCR-Ag clusters first form upon initial contact of the B-cell and APC. These initial clusters increase in size as the B-cell spreads and extends across the APC surface via cycles of protrusion and retraction. Little centripetal movement of clusters occurs in this cell. Peripheral F-actin retrograde flow is not detectable in the time-lapse sequence (perhaps the time interval is too long to detect it). In this sequence, a single BCR-Ag microcluster was observed to move centripetally \~1µm before merging into an existing larger cluster (this movement was analyzed by kymography in Figure 1E). It is striking that as BCR-Ag clusters expand within the growing B-cell-APC contact zone, the regions become devoid of B-cell F-actin, a point that may be relevant to formation or stability of the emerging SMAC. There are no predominant F-actin structures flowing centripetally during formation of the SMAC. Indeed, BCR-Ag clusters expand in size and often coalesce with each other, but they do not appear to experience much directed retrograde flow; many simply expand in place or merge upon contact with neighboring clusters.

3\) In video 3, the authors observe the behavior of B-cells spreading on a rigid glass IgG-coated coverslip using GFP-F-tractin probe. The authors describe B-cell behavior on glass as having long-lived membrane protrusions with no obvious membrane retraction events over the 10 min sequence. In contrast, the well-spread cell in video 3 exhibits dynamic membrane extension (lamellipodia and filopodia) and retraction around its circumference during the entire 10 min sequence. Moreover, one could quantify the rate of retrograde flow in this well-spread cell because the rate of time-lapse collection is sufficient to capture lamellipodial retrograde flow in some regions. The authors conclude that B-cells encountering antigen on an APC display complex and dynamic membrane probing and retraction behavior compared to when they are on glass. This appears to be the case, however, a comparison with B-cells spread on glass is comparing apples and oranges, especially when different rates of time-lapse collection are used. Nonetheless, it is important to describe observed cell behaviors and cluster dynamics as accurately as possible. To observe B-cells spreading on APCs may require different imaging modalities (faster image acquisition, additional focal planes) to appreciate its complex and intriguing behaviors.

4\) Experiments aimed at blocking Arp2/3 complex activity implicated Arp2/3 complex in coalescence of BRC-Ag microclusters to form SMAC structures. The effects on BCR-Ag cluster dynamics were slightly different for Arp3 siRNA-mediated depletion compared to pharmacologic inhibition using CK-666; specifically, several examples of clusters experiencing centripetal flow are observed in the cell treated with Arp3 siRNA (Video 5). Additionally, in the cell treated with CK-666, the nature of cluster formation is quite different from that in cells depleted of Arp2/3 complex using siRNA; clusters are linear and appear to align and expand along filopodial-like protrusive structures. What accounts for this difference in formation and behavior of clusters under these two conditions?

5\) Requirement of retrograde flow to form a SMAC. The authors do not provide compelling evidence in support of a role for Arp2/3-mediated retrograde flow in SMAC formation in B-cell-APC pairs. However, since they demonstrate that washout of CK-666 restored upregulation of CD69, a downstream effect of BCR-induced B cell activation (Figure 9---figure supplement 3), a question is whether or not a SMAC will form in B-cell-APC pairs upon washout of CK666. If the appropriate time-lapse imaging were used to simultaneously observe GFP-F-tractin in B-cells during washout of a CK-666 block, direct observations of F-actin retrograde flow and cluster flow during SMAC formation may be possible.

6\) Finally, centripetal retrograde flow could be driven by a myosin-dependent process. This could be examined directly using inhibitors of myosin II. Disruption of global Arp2/3 complex actin networks is expected to exert perturbations on the whole cell cytoskeleton. Pinpointing the specific Arp2/3 dependent-activities during B-cell signaling will be challenging using this somewhat sledge-hammer approach.

Regarding essential experiments, as discussed above the videos are quite instructive in that the A20 cell synapse has a \<1 µm rim of centripetal F-actin flow that transitions rapidly into \< 1 µm myosin arc zone that leave the BCR microclusters in a loose assembly of \~1 µm BCR-Ag clusters/condensates scattered across a large area \>5 µm in diameter. The final stage of \"cSMAC\" formation looks more like condensate fusion than transport. The tests for this would be different than for cytoskeletal transport. One way or the other, BCR consolidates in the center, but the F-actin appears to be permitting this rather than driving it. In the Arp3 KD the filopodia display robust centripetal F-actin flow as expected so the BCR clusters are transported similarly to the control siRNA, but there appear to be greater barriers to consolidation of the BCR clusters, so perhaps F-actin structures under these conditions are less permissive along the lines of work of Batista on F-actin constraining BCR movement. The CK666 seems to kill both the flow in the filopodia and create barriers to condensate fusion, so it is a very different picture that looks \"poisoned\" with the cell being paralysed in an unexpected way. The critical experiment that should be done is to use CK666 in the Arp3 KD to determine if CK666 has effects that go beyond the best Arp3 KD you can achieve in A20? If so, it could be because of incomplete KD, dominant effects of how CK666 inhibits Apr2/3, or off target effects perhaps also targeting cellular energy. Reversibility of CK666 effects would be good to see, but might not address the issues as any toxicity that makes the effects different than the Arp3 siRNA might also be reversed. In these experiments and controls, the authors could be asked to ensure that the frequency of imaging is optimised to best reveal proposed transport processes and to distinguish these from other non-correlated events. What is hoped is that this complete set of experiments (that completes the matrix of conditions set out in the study) will resolve if CK666 has activities that are beyond Arp3 siRNA (and thus could be off target) and are all of the events associated with cSMAC formation truly correlated with F-actin mediated transport or are their processes that are either independent or even hindered by some F-actin structures. Analysis of diffusive movement or random transport of the microclusters could aid identifying/discussing underlying mechanisms.

10.7554/eLife.44574.045

Author response

> Essential revisions:
>
> The major concern with the otherwise excellent study is that the authors may overreach in some interpretations and there is some concern that the CK666 displays effects that go beyond the Arp3 siRNA, raising issues about interpretations based on CK666 using in this way (1 hr pretreat at 100 µM).
>
> 1\) Video 1 (Figure 1B) shows the process of BCR-Ag clustering and SMAC formation over time. Clusters appear (t=0-1min), presumably upon B-cell contact, clusters move \~1µm centripetally where they coalesce into larger assemblies t=2-3 min), a few straggler clusters flow into the central array (t=3-5 min) and a SMAC assembly forms by \~10 min) although the forces acting on clusters and driving coalescence into a single SMAC structure are not obvious. The example illustrated in this video is unique. BCR-Ag formation and clustering in other cells shown in other videos do not exhibit all of these properties. Specifically, centripetal movement of BCR-Ag clusters is not commonly observed.

We have addressed these comments in the following ways:

1\) The reviewer is correct in that it is mainly the BCR microclusters that form at the periphery of the B cell-APC contact site, especially on newly-formed membrane protrusions, that move centripetally. To more accurately describe overall BCR microcluster movement, we now state "When A20 murine B-lymphoma cells expressing the HEL-specific D1.3 transgenic BCR (A20 D1.3 B cells) were added to the APCs, they rapidly formed BCR-Ag microclusters throughout the contact site. Microclusters that formed at the periphery moved centripetally. Closer to the center of the contact site, microclusters coalesced with each other such that a cSMAC developed within \~10 min (Figure 1B)."

2\) We now show additional videos of microcluster dynamics in control cells (4 control siRNA-transfected cells in Video 4 and 4 CK-689-treated cells in Video 6). In these videos, a number of BCR microclusters are seen to move centripetally. To illustrate this, we now show additional kymographs of microclusters that exhibit centripetal movement in Figure 2---figure supplement 4G, H, including one in which two microclusters both move centripetally before coalescing. The reader is referred to these additional videos and kymographs in the third paragraph of the subsection "The Arp2/3 complex is required for centralization of BCR-Ag microclusters".

3\) For all of the cells (18-48 cells per condition) that had been previously quantified in Figure 2E, F and Figure 2---figure supplement 3), we now quantify the centripetal movement of BCR microclusters. To do this, we calculated for every frame in the video the distance between each microcluster and the center of mass of the Ag fluorescence (which at later times, this is the center of the cSMAC). The average value for all of the microclusters on a single cell was determined at each time point and was normalized to the maximum average distance for that cell. These new graphs (Figure 2---figure supplement 4E, F) show that, on average, net microcluster movement towards the center of the cell is minimal when the Arp2/3 complex is inhibited. The reader is referred to these additional graphs in the aforementioned paragraph.

With regard to the forces that promote the condensation of aggregated microclusters within the actin-depleted regions, this process may be driven by other cytoskeletal forces such as actomyosin contraction or microtubule-based mechanism. We note this in the Discussion (fifth paragraph).

> 2\) To assess BCR-Ag clustering and SMAC formation together with B-cell F-actin structures, the authors use F-tractin-GFP to visualize dynamic B-cell actin structures and BCR-Ag clustering after B-cells contact an APC (Video 2). BCR-Ag clusters first form upon initial contact of the B-cell and APC. These initial clusters increase in size as the B-cell spreads and extends across the APC surface via cycles of protrusion and retraction. Little centripetal movement of clusters occurs in this cell. Peripheral F-actin retrograde flow is not detectable in the time-lapse sequence (perhaps the time interval is too long to detect it). In this sequence, a single BCR-Ag microcluster was observed to move centripetally \~1µm before merging into an existing larger cluster (this movement was analyzed by kymography in Figure 1E). It is striking that as BCR-Ag clusters expand within the growing B-cell-APC contact zone, the regions become devoid of B-cell F-actin, a point that may be relevant to formation or stability of the emerging SMAC. There are no predominant F-actin structures flowing centripetally during formation of the SMAC. Indeed, BCR-Ag clusters expand in size and often coalesce with each other, but they do not appear to experience much directed retrograde flow; many simply expand in place or merge upon contact with neighboring clusters.

We agree with the reviewer(s) and some of these points were addressed in our response to comment \#1. We have inserted additional statements into the text that highlight the distinction between the centripetal movement of microclusters that form within actin-rich regions (especially those that form on membrane protrusions) and those that are closer to the center of the cell and which coalesce and condense in these actin-depleted regions (subsection "B cells generate dynamic actin-rich protrusions to scan for Ags on APCs", second paragraph).

Moreover, we now show kymographs of additional microclusters exhibiting centripetal motion within actin-rich regions (Figure 1E). With regard to the kymograph shown in Figure 1E, we more clearly indicate that this refers specifically to microclusters that form in actin-rich regions and now state: "BCR-Ag microclusters formed within actin-rich regions, including newly formed protrusions Figure 1C, Video 2). \[...\] As determined from the kymographs in Figure 1E, the velocities at which the peripheral F-actin structures and BCR-Ag microclusters moved towards the center of the synapse were similar, suggesting that actin dynamics drive the initial centripetal movement of these microclusters."

The reviewer is correct that the peripheral F-actin flow is not obvious in the time-lapse series shown in Figure 1C because the time intervals are too large. However, they are clearly evident in Video 2, from which these still images are taken from, and in the kymographs in Figure 1E.

> 3\) In video 3, the authors observe the behavior of B-cells spreading on a rigid glass IgG-coated coverslip using GFP-F-tractin probe. The authors describe B-cell behavior on glass as having long-lived membrane protrusions with no obvious membrane retraction events over the 10 min sequence. In contrast, the well-spread cell in video 3 exhibits dynamic membrane extension (lamellipodia and filopodia) and retraction around its circumference during the entire 10 min sequence. Moreover, one could quantify the rate of retrograde flow in this well-spread cell because the rate of time-lapse collection is sufficient to capture lamellipodial retrograde flow in some regions. The authors conclude that B-cells encountering antigen on an APC display complex and dynamic membrane probing and retraction behavior compared to when they are on glass. This appears to be the case, however, a comparison with B-cells spread on glass is comparing apples and oranges, especially when different rates of time-lapse collection are used. Nonetheless, it is important to describe observed cell behaviors and cluster dynamics as accurately as possible. To observe B-cells spreading on APCs may require different imaging modalities (faster image acquisition, additional focal planes) to appreciate its complex and intriguing behaviors.

We agree that the membrane dynamics of B cells spreading on immobilized anti-Ig versus an Ag-bearing APC are very different phenomena and that it is sufficient to describe the behaviors without belaboring the differences. Hence we replaced the section of the original manuscript, with what we feel is a more accurate description of the mode in which B cells spread on immobilized anti-Ig. Importantly, we have qualified our statement about how this differs from B cells probing the surface of an APC. We now say: "B cells spreading on immobilized anti-Ig formed multiple large lamellipodia, some of which persisted for up to 10 min (for example, Figure 1F \[blue arrowheads\]). They also formed short dynamic filopodia, many of which were retracted or engulfed by newly formed lamellipodia."

With regard to quantifying the rate of actin retrograde flow in B cells spreading on immobilized anti-Ig, we did this in Figure 3E and Video 8 and conclude: "In control CK-689-treated cells (Figure 3E, Video 8), the F-actin networks were highly dynamic at the cell edge, with actin retrograde flow rates of \~2.5 μm/min".

> 4\) Experiments aimed at blocking Arp2/3 complex activity implicated Arp2/3 complex in coalescence of BRC-Ag microclusters to form SMAC structures. The effects on BCR-Ag cluster dynamics were slightly different for Arp3 siRNA-mediated depletion compared to pharmacologic inhibition using CK-666; specifically, several examples of clusters experiencing centripetal flow are observed in the cell treated with Arp3 siRNA (Video 5). Additionally, in the cell treated with CK-666, the nature of cluster formation is quite different from that in cells depleted of Arp2/3 complex using siRNA; clusters are linear and appear to align and expand along filopodial-like protrusive structures. What accounts for this difference in formation and behavior of clusters under these two conditions?
>
> Regarding essential experiments, as discussed above the videos are quite instructive in that the A20 cell synapse has a \<1 µm rim of centripetal F-actin flow that transitions rapidly into \< 1 µm myosin arc zone that leave the BCR microclusters in a loose assembly of \~1 µm BCR-Ag clusters/condensates scattered across a large area \>5 µm in diameter. The final stage of \"cSMAC\" formation looks more like condensate fusion than transport. The tests for this would be different than for cytoskeletal transport. One way or the other, BCR consolidates in the center, but the F-actin appears to be permitting this rather than driving it. In the Arp3 KD the filopodia display robust centripetal F-actin flow as expected so the BCR clusters are transported similarly to the control siRNA, but there appear to be greater barriers to consolidation of the BCR clusters, so perhaps F-actin structures under these conditions are less permissive along the lines of work of Batista on F-actin constraining BCR movement. The CK666 seems to kill both the flow in the filopodia and create barriers to condensate fusion, so it is a very different picture that looks \"poisoned\" with the cell being paralysed in an unexpected way. The critical experiment that should be done is to use CK666 in the Arp3 KD to determine if CK666 has effects that go beyond the best Arp3 KD you can achieve in A20? If so, it could be because of incomplete KD, dominant effects of how CK666 inhibits Apr2/3, or off target effects perhaps also targeting cellular energy. Reversibility of CK666 effects would be good to see, but might not address the issues as any toxicity that makes the effects different than the Arp3 siRNA might also be reversed. In these experiments and controls, the authors could be asked to ensure that the frequency of imaging is optimised to best reveal proposed transport processes and to distinguish these from other non-correlated events. What is hoped is that this complete set of experiments (that completes the matrix of conditions set out in the study) will resolve if CK666 has activities that are beyond Arp3 siRNA (and thus could be off target) and are all of the events associated with cSMAC formation truly correlated with F-actin mediated transport or are their processes that are either independent or even hindered by some F-actin structures.

As shown in Figure 2---figure supplement 1, the Arp3 KD is not complete, so there is likely some residual Arp2/3 activity in the siRNA-transfected cells. We feel that this is the most likely explanation for why CK-666 has a more profound effect on actin and BCR microcluster dynamics/organization. We feel that the proposed experiment in which we would treat Arp3 siRNA-transfected cells with CK-666 would not distinguish between the drug inhibiting the activity of the residual Arp2/3 complexes in the KD cells from potential off-target effects of the drug. With regard to the comment that BCR microclusters in CK-666-treated and Arp3 siRNA-transfected cells exhibit different morphology and movement, we feel that this is largely attributable to the unique morphological changes and actin remodeling exhibited by different B cells when they interact with APCs that have complex plasma membrane organization. To address this, associated with Figure 2A, B we now show videos of BCR microcluster movement in 4 representative CK-689-treated, CK-666-treated, control siRNA-transfected, and Arp3 siRNA-transfected cells (Videos 4-7) instead of just one representative cell for each condition. Importantly, to extend these analyses to larger numbers of control and Arp2/3 complex-inhibited cells, we have quantified BCR microcluster movement and cSMAC formation in multiple ways. These quantitative analyses show that, when averaged over tens of cells, the inhibition of BCR microcluster dynamics is inhibited to a similar extent by CK-666 and Arp3 siRNA. This is true for average BCR microcluster area (Figure 2E, F; note that the y-axis scales on panels E and F are different), the number of BCR-Ag clusters per cell (Figure 2---figure supplement 4C, D), the average distance of BCR microclusters from the center of total Ag fluorescence (new data in Figure 2---figure supplement 4E, F), and the number of clusters required to contain 90% of the Ag fluorescence (Figure 2---figure supplement 4I, J). Moreover, we show that CK-666 and Arp3 siRNA inhibit cSMAC formation to the same extent. In these experiments, \~15% of the CK-666-treated and Arp3 siRNA-transfected cells are still able to form cSMACs (Figure 2A, B). Consistent with this, some microclusters do exhibit centripetal movement in the CK-666-treated and Arp3 siRNA-treated cells.

With regard to the possibility that the CK-666 is poisoning the cells or targeting cellular energy generation, BCR signaling in response to soluble Ags is completely normal in the presence of CK-666 (Figure 6D, Figure 6---figure supplement 2B, Figure 8---figure supplement 1B). Moreover, PMA-induced upregulation of CD69 and CD86 is unaffected by the presence of CK-666 for the entire 18 hr duration of this experiment (Figure 9E). Finally, we also used flow cytometry to directly show that treating primary B cells with CK-666 for up to 24 hr did not result in significant cell death (Figure 2---figure supplement 2A, B, referred to in the first paragraph of the subsection "The Arp2/3 complex is required for centralization of BCR-Ag microclusters").

In our response to previous comments, we indicated that we agree with the reviewer and now describe more clearly that centripetal movement of microclusters occurs in actin-rich regions whereas within actin-depleted microclusters aggregate and condense. Specifically, we added the following sentences:

"\[...\] these data suggest that Arp2/3 complex-dependent actin structures encage BCR-Ag microclusters, such that the actin retrograde flow drives their initial centripetal movement. This appears to be required for the subsequent formation of a cSMAC, which occurs in the actin-depleted central region of the cell."

The reviewer notes that microclusters within actin-depleted regions of the CK-666-treated and Arp3 siRNA-transfected cells appear not to coalesce to the same extent as those in actin-depleted regions of control cells. In the fifth paragraph of the Discussion, we discuss how microtubules may mediate the centripetal movement of BCR microclusters across the actin-depleted central region of the contact site and facilitate the final stages of cSMAC formation. In this paragraph we note that the formation of branched actin at the periphery of the immune synapse is required for capturing the plus ends of microtubules and for moving the microtubule network towards the Ag-presenting surface. Hence, Arp2/3 complex activity may be a prerequisite for the microtubule-based centralization that leads to cSMAC formation.

> Analysis of diffusive movement or random transport of the microclusters could aid identifying/discussing underlying mechanisms.

Distinguishing random diffusion from directed super-diffusive motion would indeed be interesting but is not practical in our system because the B cells are also moving on the surface of the APC to some extent. Hence, this type moment scaling spectrum analysis is not feasible in this system.

> 5\) Requirement of retrograde flow to form a SMAC. The authors do not provide compelling evidence in support of a role for Arp2/3-mediated retrograde flow in SMAC formation in B-cell-APC pairs.

We have endeavored to clarify this point and to be more precise about the requirement of Arp2/3 complex function versus retrograde flow in cSMAC formation (which we define as \>90% of the total Ag fluorescence be contained in 1-2 large central clusters). In describing how inhibiting the Arp2/3 complex impairs cSMAC formation (Figure 2), we state: "The failure to form a cSMAC when the Arp2/3 complex is depleted or inhibited was due to decreased merger of individual BCR microclusters into larger clusters ... Thus, BCR-mediated gathering of APC-bound Ags into a cSMAC at the center of the synapse is strongly dependent on the functions of the Arp2/3 complex."

We go on to say in the Discussion that our data are consistent with Arp2/3 complex-dependent retrograde flow within actin-rich regions being an initial *requisite* step in cSMAC formation. The coalescence of BCR microclusters in the central actin-depleted regions of the cell may not be directly dependent on the Arp2/3 complex and likely does not involve actin retrograde flow. Specifically, in the first paragraph of the Discussion, we say that Arp2/3 complex activity, which generates retrograde actin flow, facilitates the initial centripetal movement of BCR microclusters and is required for cSMAC formation. We also say that "\[...\] inhibiting Arp2/3 complex activity may block a critical initial step in BCR-Ag microcluster centralization".

We feel that these are precise and accurate statements as they implicate Arp2/3 complex function in cSMAC formation but do not imply that the coalescence of BCR microclusters into a cSMAC within the actin-depleted central region of the cell is dependent on actin retrograde flow.

> However, since they demonstrate that washout of CK-666 restored upregulation of CD69, a downstream effect of BCR-induced B cell activation (Figure 9---figure supplement 3), a question is whether or not a SMAC will form in B-cell-APC pairs upon washout of CK666. If the appropriate time-lapse imaging were used to simultaneously observe GFP-F-tractin in B-cells during washout of a CK-666 block, direct observations of F-actin retrograde flow and cluster flow during SMAC formation may be possible.

Confirming that washing out the CK-666 drug restores BCR microcluster coalescence and cSMAC formation, and that this correlates with the restoration of CD69 upregulation (which had been shown in Figure 9---figure supplement 4 of the original manuscript) is an excellent suggestion. We have now carried out such an experiment using fixed cell imaging, which was sufficient to demonstrate that this is in fact the case. These new data are shown in Figure 9---figure supplement 4B-D. We now say "Once the drug was removed, the cells recovered their ability to aggregate BCR microclusters and form a cSMAC (Figure 9---figure supplement 4B-D) and B cell activation could proceed normally, consistent with the effects of CK-666 on actin dynamics being rapidly reversible (Yang et al., 2012)."

> 6\) Finally, centripetal retrograde flow could be driven by a myosin-dependent process. This could be examined directly using inhibitors of myosin II. Disruption of global Arp2/3 complex actin networks is expected to exert perturbations on the whole cell cytoskeleton. Pinpointing the specific Arp2/3 dependent-activities during B-cell signaling will be challenging using this somewhat sledge-hammer approach.

We addressed this question by using pnBB to directly inhibit myosin and now show in Figure 9---figure supplement 5C, D that this does not prevent BCR microclusters from coalescing into a cSMAC, a process that we demonstrated is dependent on Arp2/3 complex activity and is associated with microcluster centripetal movement that is mediated by actin retrograde flow. This argues that the Arp2/3 complex does not act via a myosin-dependent process to drive centripetal movement of BCR microclusters.

However, the role of myosin in B cell responses to APC-bound Ags is an interesting question and we have now addressed this in Figure 9---figure supplement 5A, B. We found that treating primary B cells with pnBB caused a small decrease in the upregulation of CD69 or CD86, which was not statistically significant (i.e. p\>0.05). This is in contrast to the Arp2/3 complex inhibitor CK-666, which caused significant reductions in these B cell activation responses. This indicates that the Arp2/3 complex has a more important role in APC-induced B cell activation than myosin. These new experiments are described in the sixth paragraph of the Results subsection "Arp2/3 complex activity is important for BCR-induced B cell activation responses".
